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3.  ABBREVIATIONS
ACI  autologous chondrocyte implantation 
ACL  anterior cruciate ligament 
ADASC             adipose-derived adult stromal cell 
ALK  activin receptor-like kinase 
alloHS  allogeneic human serum 
AP  alkaline phosphatase 
APC  allophycocyanin 
ApoE  apolioprotein E 
Arg  arginine 
AS   autologous serum 
b-FGF  basic fibroblastic growth factor 
BM  bone marrow 
BMI  body mass index 
BMMNC bone marrow mononuclear cell 
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DNase  deoxyribonuclease 
Dnmt  DNA methytransferase 
dpc  days postcoitum 
Dvl  dishevelled 
EB  embryoid body 
EC  endothelial cell 
ECM  extracellular matrix 
EDTA  ethylenediaminetetra acetic acid 
EGC  embryonic germ cell 
ESC  embryonic stem cell 
FBS  fetal bovine serum 
FGF  fibroblast growth factor 
FITC  fluorescein isothiocyanate 
Fz  frizzled 
GAG  glycosaminoglycan 
GSK  glycogen synthase kinase 
GVDH  graft versus host disease 
H  histone 
H3K9  histone H3, K9 
H3K9ac            acethylation of H3K9 
H3K9m            methylation of H3K9 
HA  hyaluronic acid 
HA/TCP hydroxyapatite tricalcium phosphate 
hAS  human articular chondrocyte 
HDAC  histone deacetylase 
hESC  human embryonic stem cell 
Hg  hedgehog 
HLA  human leukocyte antigen 
hLP  human platelet 
hMSC  human mesenchymal stem cell 
HRPO  horseradish peroxidase 
HSC  hematopoietic stem cell 
ICM  inner cell mass 
IDO  indoleamine 2, 3-deoxygenase 
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IFN  interferon 
IGF-I  insulin-like growth factor-I 
Ihh  Indian hedgehog 
IL  interleukin 
ISCT  international society for cellular therapy 
ITS  insulin transferring sodium selenite 
JAK  janus kinase 
K  lysine 
LIF  leukaemia inhibitory factor 
LRP  lipoprotein receptor-related protein 
Lys  lysine 
MAb  monoclonal antibody 
MAPC  multipotent adult progenitor cell 
MAPK  mitogen-activated protein kinase 
MAS  affymetrix microarray suite 
MECP  methyl-CpG-binding protein 
mESC  mouse embryonic stem cell 
MHC  major histocompatibility 
MMP  matrix metalloproteinase  
mRNA  messenger ribonucleic acid 
MSC  mesenchymal stem cell 
N-cadherin neural cadherins 
N-CAM  neural cell adhesion molecule 
NK  natural killer 
NOD  non-obese diabetic 
OA  osteoarthritis 
PAGE  polyacrylamide gel electrophoresis 
PBMC  peripheral blood mononuclear cell 
PCM  pericellular matrix 
PCR  polymerase chain reaction 
PDGF  platelet-derived growth factor 
PE  phycoerythrin  
PECAM  platelet endothelial cell adhesion molecule 
PerCP  peridinin chlorophyll 
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PGC  primordial germ cell 
PL  platelet lysate 
Pthlh  parathyroid hormone-like peptide 
RNA  ribonucleic acid   
RT  reverse transcriptase 
RTK  receptor tyrosine kinase 
RT-PCR  real-time PCR 
SDF-1  stromal derived factor-1 
SDS  sodium dodecylsulfate 
Ser  serine 
SREBF2 sterol regulatory element binding transcription factor 2 
SSC  spermatogonial stem cell 
STAT  signal transducer and activators of transcription 
SVF  stromal vascular fraction 
TAZ  transcriptional coactivator with PDZ-binding motif 
TBI  total body irradiation 
TGF-ȕ  transforming growth factor ȕ
Thr  threonine 
TIPs  tension-induced/-inhibited proteins 
TNF  tumour necrosis factor 
VCAM             vascular cell adhesion molecule 
VEGF  vascular endothelial growth factor 
Wnt  wingless 
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4.  INTRODUCTION 
The Greek Titan, Prometheus, is a fitting symbol for regenerative medicine. As 
punishment for giving fire to humankind, Zeus ordered Prometheus chained to a rock 
and sent an eagle to eat his liver each day. However, Prometheus´ liver was able to 
regenerate itself daily, enabling him to survive. 
4.1  Stem cells 
Stem cells have the remarkable potential to develop into many different cell types and 
are defined by both their ability to make more cells, a property known as self-renewal,
and their ability to produce cells that differentiate. 
There are three kinds of stem cells: embryonic, germinal, and somatic or adult stem 
cells. Embryonic stem cells are derived from the first five or six divisions of the 
fertilized egg. The progeny of embryonic stem cells are the precursors for all of the cells 
of the adult organs. Germinal stem cells in the adult produce eggs and sperm and are 
responsible for reproduction. Somatic stem cells are considered more limited in their 
potential, and they produce cells that differentiate into mature functioning cells that are 
responsible for normal tissue renewal (Sell, 2004). 
4.2  Embryonic stem cells 
The first entity of life, the fertilized egg, has the ability to generate an entire organism. 
This capacity, defined as totipotency, is retained by early progeny of the zygote up to the 
eight-cell stage of the morula. Subsequently, cell differentiation results in the formation 
of a blastocyst composed of outer trophoblast cells and undifferentiated inner cells, 
commonly referred to as the inner cell mass, ICM. Cells of the ICM are no longer 
totipotent but retain the ability to develop into all cell types of the embryo, defined as 
pluripotent embryonic stem cells (ESC) (Wobus and Boheler, 2005) (Figure 1). 
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Figure1. Generation of pluripotent embryonic stem cells. 
Human pluripotent embryonic stem cells have been derived from in vitro cultured ICM 
cells of blastocyst after in vitro fertilization (from Wobus AM.and et.al. 2005, with 
permission of The American Physiological Society). 
Embryonic stem cell (ESC) lines from mouse (Evans and Kaufman, 1981; Martin, 
1981), human (Thomson et al., 1998) blastocysts and, as recently shown, derived from 
single blastomeres, any one of the cells formed by the first divisions of a fertilized egg 
(Chung et al.,2006; Klimanskaya et al., 2006) have been established. 
Stem cells from various adult organs that self-renew and differentiate into multiple 
organ specific cell types are termed multipotent stem cells. Committed cells that have 
limited or no self-renewal ability and differentiate into only one defined cell type are 
termed progenitor or precursor cells (Lakshmipathy and Verfaillie, 2005). 
4.2.1  Human and mouse embryonic stem cells  
ESC forms tight colonies with sharp borders when grown in vitro in culture dishes. 
From the morphological point of view, mouse embryonic stem cells (mESCs) grow as 
aggregates, but human embryonic stem cells (hESCs) grow as flat colonies. The 
population doubling time of hESCs is significantly longer than that of mESCs, possibly 
reflecting the longer gestational period in humans than in mice. Furthermore, hESCs 
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differentiate more readily and show much lower cloning efficiency compared to mESCs 
(Scholz et al., 1999; Thomson et al., 1998). Although many signaling pathways are 
conserved in animal development (transforming growth factor E (TGF-E) superfamily, 
receptor tyrosine kinase (RTK), Wingless (Wnt), Hedgehog (Hg), JAK/STAT and notch 
signaling (Pires-daSilva and Sommer, 2003), several key differences have already 
emerged, particularly the mechanisms underlying self-renewal, cell surface marker 
expression, signaling pathways and differentiation ability. 
4.2.2  Self-renewal and pluripotency of ESCs 
In vivo, during mouse embryogenesis, the primitive ectoderm of the epiblast forms three 
primary germ layers: the ectoderm, the mesoderm, and the definitive endoderm. These 
germ layers interact to form all tissues and organs of the developing embryo. The 
differentiation potential of mESCs in vitro has facilitated the examination of these 
processes. Once differentiation has begun, ESCs will aggregate into three-dimensional 
clusters of cells in an early stage of differentiation, thereby losing pluripotency. These 
clusters, named Embryoid Bodies (EBs), form the first step of further differentiation 
into any type of progeny. Within the EBs, a microenvironment exists in which various 
signals will promote differentiation into all three germ layers (van der Bogt et al., 2006). 
Initially, an outer layer of endoderm-like cells forms within the EB, followed over a
period of a few days by the development of an ectodermal layer and subsequent 
specification of mesodermal cells. These EBs in tissue culture plates allow for 
continued differentiation into a variety of specialized cell types including cardiac,
smooth and skeletal muscle as well as hematopoietic, pancreatic, hepatic, lipid, 
cartilage, or neuronal and glial cells. The temporal expression of tissue-specific genes
and proteins in mES-derived cells during in vitro differentiation indicates that early 
processes of in vivo development into ectoderm, mesoderm and endoderm lineages are 
recapitulated in vitro (Wobus and Boheler, 2005). In a similar manner, hESCs 
spontaneously differentiate into EBs composed of three embryonic germ layers in vitro 
(Itskovitz-Eldor et al., 2000). 
Derived from the ICM of the blastocyst, ESCs can proliferate indefinitely in vitro (self-
renewal) and differentiate into cells of all three germ layers (pluripotency). These 
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unique properties make them exceptionally valuable for cell replacement therapies, drug 
discovery and regenerative medicine. 
An interesting feature of these cells is that self-renewal happens indefinitely without 
loss of pluripotency. The mechanisms of this unique ability are still not well known, but 
several extrinsic factors support the self-renewal of ESCs in vitro. Leukemia inhibitory 
factor (LIF) supports the undifferentiated state of mESCs by activating the signal 
transducer STAT3. Another extrinsic factor known to support mESCs self-renewal is 
BMP4. In the presence of LIF, BMP4 can enhance the self-renewal and pluripotency of 
mESCs by activating inhibitor of differentiation (Id) genes (Ying et al., 2003). In 
addition to LIF and BMP4, the Wnt pathway is sufficient to maintain self-renewal of 
mESCs and hESCs (Sato et al., 2004). Under conditions that would promote self-
renewal of mESCs, LIF is not sufficient to maintain hESCs self-renewal and BMPs 
cause rapid differentiation. Instead, FGF signaling and the balance between 
TGFȕ/activin and BMP signaling appear central to the self-renewal of hESCs (Xu et al., 
2005; James et al., 2005; Vallier et al., 2005). 
At the molecular level, pluripotency has been linked to a few transcription factors and 
their expression appears to define whether a cell should be pluripotent. The best 
characterized of these is OCT4, which functions to maintain pluripotency both in vivo
and in vitro. Oct4 is a transcriptional factor that is specially expressed in all pluripotent 
cells during mouse embryogenesis and also in undifferentiated ESCs (Pan et al., 2002). 
However, OCT4 is not the only master gene that controls ESCs pluripotency. Recently, 
another master gene in ESCs pluripotency, Nanog, was discovered. Nanog is a unique 
homeobox transcription factor that plays a critical role in regulating the cell fate of the 
pluripotent ICM during embryonic development, maintaining the pluripotent epiblast 
and preventing differentiation to primitive endoderm (Chambers et al., 2003). 
4.2.3  Signaling pathways in ESCs 
The unique property of ESCs has opened new possibilities for studying differentiation 
in early human embryo development, more importantly to understand the underlying 
molecular mechanisms that control cell growth and differentiation in vitro. Furthermore, 
hESCs and their derivatives have great potential for developing cell therapies for 
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treatment of ailments such as diabetes, Parkinson’s disease and heart failure. However, 
fabrication of both undifferentiated and differentiated hESCs requires improved control 
of regulatory mechanisms of differentiation before transplantation of hESCs becomes 
clinically applicable. 
However, if undifferentiated hESCs were to be transplanted into immunosuppressed 
patients, it is possible that they would form teratomas or teratocarcinomas (generation 
spontaneous tumors from ESCs) containing a mixture of tissue types. It is therefore of 
great importance to understand the signaling pathways that direct hESCs along a given 
differentiation path. Following is a brief description of some of the more important 
families of molecules known to be involved in stem cell differentiation. 
4.2.3.1  TGF-E superfamily 
TGF-E is a multipotent growth factor that is involved in regulating cell growth, 
differentiation, migration, extracellular matrix (ECM) deposition and apoptosis during 
embryonic development and adult homeostasis and response to injury and diseases 
(Valdimarsdottir and Mummery, 2005). TGF-E superfamily signals are conveyed 
through serine/threonine kinase receptors to specific intracellular mediators known as 
Smad proteins (Massague, 2000; Roberts et al., 1986). Vertebrates possess at least eight 
Smad proteins falling into three functional classes: (1) Receptor activated Smads 
(RSmads): Smad1, Smad2, Smad3, Smad5 and Smad8, (2) Comediator Smads: Smad4 
and Smad10, (3) Inhibitory Smads: Smad6 and Smad7. This superfamily has more than 
40 members, including TGF-E, activin, nodal and bone morphogenetic proteins (BMPs) 
(Massague, 1998; Roberts et al., 1986). These ligands have all been associated with ES 
cells. The TGF-ȕ prototype transduces signals from the membrane to the nucleus by 
binding to a heteromeric complex of serine/threonine kinase receptors known as TGFȕ
type I (TȕRI) and type II (TȕRII) receptors (Figure 2). The type I receptor, also known 
as activin receptor-like kinase (ALK), acts downstream of the type II receptor and 
propagates the phosphorylation signal through specific downstream Smad mediators. 
The Smads enter the nucleus, where they activate transcription of their target genes 
(Heldin et al., 1997; Piek et al., 1999; Massague, 2000) (Figure 2). 
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Figure 2. The TGF-ȕ signal transduction pathway.
(from Valdimarsdottir G. and et.al. 2005, with permission of Wiley-Blackwell 
Publishing Ltd.). 
The TGF-ȕ family members have been reported to regulate multiple aspects of ESC fate 
decisions. Whether ESCs undergo self-renewal or differentiation likely depend on the 
state of the cells and the levels of cytokines and their interactions with other molecules 
(Valdimarsdottir and Mummery, 2005). 
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4.2.3.2  Wnt signaling pathway 
WNT (Wingless and INT-1) genes encode small secreted proteins that are found in all 
animal genomes. Wnt signaling is involved in virtually every aspect of embryonic 
development and also controls homeostatic self-renewal in a number of adult tissues. 
Germline mutations in the Wnt pathway cause several hereditary diseases, and somatic 
mutations of WNT genes are associated with cancer of the intestine and a variety of 
other tissues. Genome sequencing has since revealed that mammalian species have 
roughly 20 secreted Wnt proteins, which can be divided into 12 conserved Wnt 
subfamilies (Clevers, 2006). Three different pathways are believed to be activated upon 
Wnt receptor activation: the canonical Wnt/ȕ-catenin cascade, the noncanonical planar 
cell polarity (PCP) pathway, and the Wnt/Ca2+ pathway (Katoh, 2005; Kohn and Moon, 
2005). The canonical pathway is the best understood, and is the subject of this section 
(Figure 3). 
                          In the absence of Wnt                                   In the presence of Wnt 
Figure 3. Canonical Wnt signalling pathway. 
(from Salinas PC. 2007, with permission of  Elsevier Limited). 
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The central player in the canonical Wnt cascade is E-catenin, a cytoplasmic protein 
whose stability is regulated by the destruction of a cytoplasmic complex. Axin acts as 
the scaffold of this complex as it directly interacts with E-catenin, APC, and the two 
kinase families, CK1 and GSK3. In the absence of Wnt proteins, Wnt receptor 
complexes are not engaged. CK1 and GSK3D/E sequentially phosphorylate E-catenin at 
a series of highly conserved Ser/Thr residues near its N terminus. Phosphorylated E-
catenin is then recognized by a component of the dedicated E3 ubiquitin ligase 
complex. As a consequence, E-catenin is ubiquitinated and targeted for rapid destruction 
by the proteasome (Aberle et al., 1997) (Figure 3). 
 In the presence of extracellular Wnt ligands, the Wnt family binds Frizzled (Fz) 
proteins, which are seven-pass transmembrane receptors with an extracellular N-
terminal cysteine–rich domain (CRD) (Bhanot et al., 1996). LRP5/6 (lipoprotein 
receptor related protein 5 or 6) act as a coreceptor for Wnt binding to Fz. The 
Fz/LRP5/6 complex activates the canonical signaling pathway. Fz can physically 
interact with Dvl, a cytoplasmic protein that functions upstream of E-catenin and the 
glycogen synthase kinase 3E (GSK-3) (Clevers, 2006). The coreceptor LRP5/6 interacts 
with Axin through five phosphorylated PPP(S/T)P repeats in the cytoplasmic tail of 
LRP (Davidson et al., 2005; Zeng et al., 2005). GSK3 phosphorylates the PPP(S/T)P 
motif, whereas CK1J phosphorylates multiple motifs close to GSK3 sites. Thus, the 
phosphorylated PPP(S/T)P motif mediates the LRP5/6-Axin interaction (Mao et al., 
2001; Tamai et al., 2004). The recruitment of Axin away from the destruction complex 
leads to stabilization of E-catenin. In the nucleus, stabilized E-catenin displaces the 
corepressor protein Groucho (Lepourcelet and Shivdasani, 2002) and interacts with 
transcription regulators; including T cell factor /leukocyte enhance factor-1 (Tcf/Lef-1) 
to promote the transcription of Wnt target genes (Dale, 1998; Gumbiner, 1998; Wodarz 
and Nusse, 1998) (Figure 3). 
4.2.4  hESCs immunogenicity 
hESCs are under extensive investigation for their regenerative potential in the treatment 
of various degenerative and malignant human diseases. The pluripotent character of 
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undifferentiated hESCs is attractive for cell-based therapy, but their pluripotency can 
also lead to risk of teratoma formation after transplantation. Another major clinical 
concern is the possibility of a provoked immune reaction after transplantation of hESCs 
into a new host, which may severely limit their use in therapeutics. Survival of 
transplanted cells correlates with the number of differences in major histocompatibility 
(MHC) antigens between donor and recipient, triggering T-cell responses and rejection
of cells with disparate MHC profiles (Janeway, Jr., 1999). Undifferentiated hESCs 
express low levels of cell surface human leukocyte antigen class I (HLA-I) molecules. 
The expression of HLA-I was elevated in EBs, with even higher levels observed in 
teratomas. However, HLA class II (HLA-II) molecules were not expressed (Draper et 
al., 2002; Drukker et al., 2002). Undifferentiated as well as differentiated hESCs 
upregulate expression of HLA-I at least 10 fold in response to interferons (IFNs). 
However, HLA-II expression was not induced, reviewed in (Drukker and Benvenisty, 
2004).
HESCs injected into the leg muscle of immunocompetent (CD-1) mice failed to induce 
an immune response 48 hours after injection. In addition, in vitro analyses showed that 
undifferentiated hESCs and EBs failed to stimulate proliferation of alloreactive primary 
human T cells (Li et al., 2004). HESCs transplanted into mice were rejected in all 
recipient strains tested, but when transplanted under the kidney capsule with 
concomitant hematopoietic reconstitution after whole body irradiation, hESCs were 
accepted and developed into teratomas (Drukker et al., 2006). 
In vitro studies and short term in vivo experiments demonstrating that hESCs are 
immune-privileged or have reduced immunogenicity are in contrast with recent studies 
in which hESCs were injected into the mouse myocardium demonstrating that hESCs 
were immunogenic in allogeneic and xenogeneic settings (Grinnemo et al., 2006). 
Microarray analysis and flow cytometry of hESC lines have shown that both HLA
classes were expressed at the mRNA level, but there was no surface expression of HLA 
class II, not even after IFNJ stimulation. It has also been demonstrated that expression 
of co-stimulatory molecules at the mRNA level was low or absent (Grinnemo et al., 
2006). Co-stimulatory molecules, such as B7-1 (CD80) and B7-2 (CD86) were not 
expressed on undifferentiated or differentiated hESCs (Sharpe and Freeman, 2002). 
Microarray analysis of molecules known to inhibit immune responses, such as FasL 
(CD59L) which has been shown to mediate induction of apoptosis in activated T- cells 
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(Green and Ferguson, 2001; Hamad and Schneck, 2001), IL-10, a cytokine important in 
reducing inflammation and utilized by regulatory T-cells in the prevention of unwanted 
immune responses (Roncarolo et al., 2001), revealed that they were not expressed in 
hESCs (Grinnemo et al., 2006). TGF-E, a key mediator in the prevention of 
autoimmune disease in various animal models (Roncarolo et al., 2001) was expressed in 
four of seven hESC lines (Grinnemo et al., 2006). Thus, the lack of expression of high 
levels of HLA class II and co-stimulatory molecules and the expression of molecules 
known to inhibit the immune response, theoretically state that ESCs cannot be 
immunogenic. But surprisingly, in some studies, hESCs induce mouse CD4+ T-cell 
proliferation equivalent to that of fibroblasts. This is probably due to the fact that all 
cells which are transplanted into a host with functional dendritic cells (DC) will have 
their antigen presented by indirect antigen presentation to the immune system 
(Grinnemo et al., 2006). 
Although these are important observations, it is also important to note that such 
knowledge does not allow for an accurate prediction of immune responses against the 
cells because multiple factors in addition to direct antigen presentation by hESCs are 
involved in such responses. Before using hESCs or their derived tissues in therapeutics, 
a complete understanding of the cellular interactions between hESCs and the immune 
system should be investigated. 
4.3  Germinal stem cells 
Following fertilization of the oocyte by a spermatozoon, the zygote begins proliferation 
and then differentiates to produce many cell types that constitute an individual. At day 5 
after fertilization in the mouse, the zygote becomes a blastocyst, and then begins the 
process of implantation. At this time, the embryo consists of ICM, primitive endoderm 
and trophoectoderm. The ICM cells are precursors of epiblast cells, which give rise to 
the three germ layers that produce stem cells for all tissues of the fetus. Epiblast cells 
gradually commit to specific cell lineages and lose pluripotent developmental potential. 
Some of these committed cells become cell linage specific primitive somatic stem cells, 
while others become primitive germline cells (Kubota and Brinster, 2006). 
About 7 days postcoitum (dpc) in the mouse, specification of the germ cell lineage 
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occurs in the proximal epiblast under the influence of surrounding extraembryonic 
tissues. At this stage, about 100 alkaline phosphatase AP positive primitive germline 
cells, which are also called primordial germ cells PGCs, are formed. PGCs are the 
founder cells for the germline. They divide symmetrically and all their descendents are 
germ cells. In many organisms, PGCs are motile and migrate to the somatic gonads. In 
the mouse, they migrate to female or male genital ridges and differentiate into oogonia 
or gonocytes, respectively (Matsui et al., 1992; McLaren, 2003; Seydoux and Braun, 
2006). Oogonia in the female gonads quickly enter meiotic prophase as oocytes, which 
are all arrested in meiosis I before birth. The adult ovary, therefore, does not contain 
germline stem cells (Kubota and Brinster, 2006). In the male, gonocytes cease mitosis 
in the seminiferous tubules of the testes and resume mitotic activity after birth. In the 
fetus, gonocytes are located in the centre of the tubules, but during the first few days 
after birth in mouse and at later times in other species, they either undergo apoptosis or 
migrate to the basement membrane in testes and become spermatogonial stem cells 
SSCs (de Rooij and Grootegoed, 1998; Orwig et al., 2002). 
4.3.1  Spermatogonial stem cells 
PGCs from embryos between 8.5 and 12.5 dpc give rise to pluripotent cells when 
cultured under appropriate conditions (Matsui et al., 1992; Resnick et al., 1992). These 
embryonic stemES/embryonic germ EG cells have differentiation properties similar 
to ES cells isolated from the inner cell mass (Evans and Kaufman, 1981; Martin, 1981). 
These observations suggest that the germline lineage may retain the ability to generate 
pluripotent cells. Germline stem cells from neonatal mouse testis are also pluripotent 
and have differentiation potential similar to embryonic stem cells (Kanatsu-Shinohara et 
al., 2004). Recently, the pluripotency and plasticity of adult spermatogonial stem cells 
SSCs, which are responsible for maintaining spermatogenesis throughout life in the 
male, has been reported. These isolated SSCs respond to culture conditions and acquire 
embryonic stem cell properties. They express ES cell markers and are able to 
spontaneously differentiate into derivatives of three embryonic germ layers in vitro and 
generate teratomas in immunodeficient mice. When injected into an early blastocyst, 
SSCs contribute to chimeras by the development of various organs and show germline 
transmission (Guan et al., 2006). Thus, the capacity to form pluripotent cells persists in 
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adult mouse testis. It is extremely fascinating that SSCs can contribute both to 
spermatogenesis and to chimera formation, indicating that SSCs appear to be able to 
change their fate quickly according to their microenvironment. No other cells in the 
body could have such diverse developmental functions at the same time. SSCs may be 
ideal cells for regenerative medicine if these findings can be reproduced with human 
cells. These cells can provide a generous supply of healthy pluripotent cells for curing 
diseases without the ethical concerns associated with ESCs. Finally, SSCs in the adult 
testis may be more versatile than ESCs (Kanatsu-Shinohara and Shinohara, 2006). 
4.4  Adult stem cells 
Developmentally, stem cells are categorized either as embryonic stem cells or as 
postnatal stem cells. These latter cells are also called organ specific, tissue specific or 
adult stem cells (Pauwelyn and Verfaillie, 2006). Adult stem cells are traditionally 
thought to be restricted in their differentiation potential to the progeny of the tissue in 
which they reside. In higher vertebrates, most adult tissues and organs contain stem 
cells capable of self-renewal, proliferation and differentiation into their own mature and 
functional progeny. These stem cells are more abundant in tissues with a high renewal 
rate, such as blood and epithelia, and less abundant in tissues or organs with little 
renewal capacity such as myocardial muscle or the central nervous system (CNS). In the 
last few years, a number of reports have claimed a broad multipotency and remarkable 
plasticity in the differentiation potential of stem cells derived from adult tissues such as 
bone marrow (BM), the skeletal musculature or the CNS. In all cases, differentiation of 
stem cells into a non-traditional progeny e.g., muscle or liver from BM stem cells, was a 
rare phenomenon (Krause et al., 2001; Okamoto et al., 2002). For instance, 
neurosphere-derived neural stem cells have been differentiated to hematopoetic stem 
cells (HSC), which contain a completely different genetic program (Bjornson et al., 
1999).
However, the origin of stem cells in adults, as well as whether they are distinct 
populations of cells or represent the remains of embryonic development, is unclear. 
Another controversy is whether adult stem cells isolated from a particular tissue 
originated in this tissue or was derived from a pool of stem cells circulating in the blood 
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that have been temporarily trapped in the tissue from which they were isolated, having 
thus been subjected to a process called homing (Korbling et al., 2002). 
More recent developments have proven that adult stem cells reside in nearly every 
tissue, including brain, bone marrow, peripheral blood, kidney and epithelia of the 
digestive system, as well as skin, retina, muscle, pancreas, liver, fat, umbilical cord, 
scalp and placenta (Keating, 2006; Slack, 2000). The possibility of a broad 
multipotential capacity of adult stem cells has obvious relevance for repair of damaged 
tissues other than the tissues in which they reside. In a part of this thesis, adult stem 
cells from human bone marrow and adipose tissue were isolated and characterized. The 
following sections highlight recent discoveries in the area of MSCs. 
4.4.1  Biology of adult mesenchymal stem cells 
Mesenchymal stem cells (MSCs) were first identified in 1966 in studies when bone/ 
cartilage forming progenitor cells from rat bone marrow cells with fibroblastic-like 
morphology were isolated (Friedenstein et al., 1966). The first description of the 
classical tri-lineage differentiation of MSCs was reported in 1999 (Pittenger et al., 
1999). Plastic adherent multipotent cells were isolated from many adult tissues and 
displayed a heterogeneous mixture of cells with varying proliferation and differentiation 
potentials. Most of the studies focused on MSCs from human and mouse bone marrow. 
Surprisingly, there is only a small amount of variations between populations, even 
among cells isolated from different sources. However, a rare cell within the human bone 
marrow mesenchymal stem cell culture was identified that can be expanded for more 
than 80 population doublings. This cell differentiates not only into mesenchymal 
lineage cells but also into endothelium and endoderm (Reyes et al., 2001; Reyes et al., 
2002; Schwartz et al., 2002). The same lab has also reported mouse bone marrow-
derived multipotent adult progenitor cells (MAPCs) that proliferate extensively without 
obvious senescence or loss of differentiation from the MSC population as a whole 
(Jiang et al., 2002a). These MAPCs differentiate, at the single cell level, not only into 
mesenchymal cells, but also into cells with visceral mesoderm, neuroectoderm and 
endoderm characteristics in vitro. MAPCs contribute to most somatic tissues when 
injected into an early blastocyst and engraft in vivo, where they differentiate into tissue 
specific cell types in response to cues provided by different organs (Jiang et al., 2002a). 
29
Many efforts have been made to develop a cell surface antigen profile for better 
purification and identification of MSCs. However, even MAPCs do not express specific 
surface markers and show similarities that may represent a more primitive pluripotent 
progenitor of MSCs. 
4.4.1.1  Adult MSC markers and nomenclature 
Many studies have reported a population of stem cells from various tissues known as 
mesenchymal stem cells, marrow stromal cells and mesenchymal stromal cells, all 
designated by the acronym MSC. These studies have shown a more or less similar 
phenotype characteristic of MSCs. Recently, the International Society for Cellular 
Therapy (ISCT) has clarified the nomenclature by introducing the term multipotent 
mesenchymal stromal cells, with the same acronym (MSCs). The minimal criteria for 
defining multipotent mesenchymal stromal cells are as follows: first, MSCs must be 
plastic-adherent when maintained in standard culture conditions. Second, MSCs must 
express CD105, CD73 and CD90, and lack expression of CD45, CD34, CD14 or 
CD11b, CD79 alpha or CD19 and HLA-DR surface molecules. Third, MSCs must 
differentiate to osteoblasts, adipocytes and chondroblasts in vitro (Dominici et al., 
2006).
4.4.1.2  Cell frequency of adult MSCs in different tissues 
MSCs are present at low numbers in BM and most other tissues. Thus, most of our 
present data on MSCs is based on cells expanded in culture. In previous studies, the 
hMSC precursor frequency has been calculated to be 2 to 5 per 106 bone marrow 
mononuclear cells (BM MNC) (Minguell et al., 2001), 1 in 104 BM MNCs based on 
selection by the D7-FIB monoclonal antibody (MAb) and colony-forming unit 
fibroblastic (CFU-F) assays, and 3 in 104 BM MNCs based on isolation of STRO-
1bright/vascular cell adhesion molecule–positive (VCAM+) cells and CFU-F assays in 
medium supplemented with growth factors(Gronthos et al., 2003b). In paper II of this 
thesis, the MSC precursor frequency in CD14+-depleted BM MNCs has been calculated 
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to be approximately 1 in 103.
In comparative analyses, colony number per 103 nucleated cells derived from synovium, 
periosteum, adipose tissue and muscle was about 100-fold higher than that derived from 
BM (Sakaguchi et al., 2005). The number of CFU-F calculated on the basis of 106
initially plated cells was highest for adipose tissue, followed by BM, and was lowest for 
umbilical cord blood (Kern et al., 2006). 
Adipose tissue is easy to obtain in large quantities and harbors a large number of cells 
with CFU-F ability (Zuk et al., 2002). In paper I, we purified the uncultured 
CD34+CD105+CD31- population from SVF of human adipose tissue using a 
combination of MAbs to cell surface antigens. About 4% of this selected population, at 
the single cell level in culture, displayed MSC characteristic. 
4.4.1.3  Adult MSC self-renewal and maintenance 
Self-renewal refers to the biological pathways and mechanisms that preserve the 
undifferentiated state of stem cells. LIF, fibroblast growth factors (FGFs) and 
mammalian homologs of Wnts among other growth factors and cytokines have been 
shown to be involved in MSC stem cell maintenance (Jiang et al., 2002b; Boland et al., 
2004; Tsutsumi et al., 2001). These factors have attracted particular attention because of 
their demonstrated role in the self-renewal of undifferentiated ESCs, which was 
discussed in sections 4.2.2 and 4.2.3 of this thesis. LIF cytokine maintains the 
undifferentiated state of MSCs and may involve paracrine crosstalk with neighboring 
cells. FGF2 also maintains the self-renewal of MSCs from a variety of species by 
prolonging their viability in culture. Target genes of FGF involved in MSC stemness are 
not known, but it is plausible that an autocrine regulatory loop may underlie FGF self-
renewal function, as during vertebrate limb development (Marie et al., 2005). Wnt3a 
treatment increases adult MSC proliferation while inhibiting osteogenic differentiation 
(Boland et al., 2004). Canonical Wnt functions include the promotion of long term 
culture expansion of stem cells, increased in vivo reconstitution of hematopoietic 
lineages and Wnt3a specific maintenance of the skin and intestinal stem cell population 
(Kleber and Sommer, 2004). The mechanism of Wnt signaling has also been described 
in section 4.2.3.2. 
MSCs from a variety of mammalian species also express the embryonic stem cell gene 
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markers OCT4, SOX2, and REX1, among others (Izadpanah et al., 2006). Recent 
chromatin immunoprecipitation array studies suggest that some polycomb chromatin-
associated proteins are involved in maintaining the repression of differentiation genes. 
Polycomb protein may indirectly maintain OCT4, SOX2, and REX1 activation in MSCs 
(Ringrose and Paro, 2004). 
4.4.1.4  Differentiation of adult MSCs 
Regulating the switch between proliferation and differentiation of MSCs is critical for 
the development of normal tissues, and the prevention of tumors. How MSCs exit from 
the cell cycle and differentiate into alternative cell fates such as bone, fat, and muscle, is 
incompletely understood. The ability to modulate biological effectors to manage a 
desired differentiation program is needed for effective clinical application, as in tissue 
engineering and regeneration. The differentiation of adult MSCs isolated from a variety 
of tissues into a number of lineages has been described. In general, extracellular 
molecular signaling and mechanical inducers of differentiation transduce effects 
through accepted receptors, channels or other cell surface associated mechanisms. 
Downstream signaling pathways, including that between distinct mitogen-activated 
protein kinases (MAPKs) and R-Smads, provides a level of specificity that gives rise to 
unique lineages, such as chondrocytes and osteoblasts. The specificity of lineage 
differentiation can also result from the recruitment of master transcriptional switches 
with binary regulation of cell fate, such as TAZ (transcriptional coactivator with PDZ-
binding motif). Depending on the potentially unique multiprotein complexes that it may 
form in response to specific upstream signaling, TAZ promotes osteogenesis and 
inhibits adipogenesis. TAZ functions as a transcriptional modulator to stimulate bone 
development while simultaneously blocking the differentiation of MSCs into fat. These 
developmental effects occurs through direct interaction between TAZ and the 
transcriptional factor Runx2 (also called Cbfa1 or Pebp2ĮA) and peroxisome 
proliferator-activated receptor J (PPARJ), resulting in transcriptional enhancement and 
repression, respectively of selective programs of gene expression (Hong et al., 2005; 
Hong and Yaffe, 2006). 
An attempt to identify common pathways mediating differentiation of MSCs into 
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osteogenic, adipogenic and chondrogenic lineages has shown that a set of genes that are 
upregulated during differentiation is needed for differentiation into all three lineages, 
whereas lineage specific late-differentiation genes are essential for terminal 
differentiation. One of the genes that appear to have a positive role in early 
differentiation of these three mesenchymal lineages is FKBP5, a binding protein 
involved in modulating hormone receptor response and transcription regulation (Liu et 
al., 2007). 
4.4.1.5  Asymmetric and symmetric stem cell division 
Stem cells are defined by both their ability to make more stem cells, self-renewal, and 
their ability to produce differentiated cells. One tactic by which stem cells can achieve 
these two tasks is asymmetric cell division, whereby each stem cell divides to generate 
one daughter with a stem-cell fate like the mother, self-renewal, and one daughter 
(committed cell) that differentiates. The benefit of asymmetric cell division is that it 
manages both tasks with a single division, and the disadvantage of asymmetric division 
is that it leaves stem cells unable to expand in number. Thus, asymmetric cell division 
alone cannot fulfill all stem cell characteristics. However, stem cells are also able to use 
symmetric cell division to generate more stem cells and differentiated daughters. In 
principal, stem cells can either depend completely on symmetric division or a 
combination of symmetric and asymmetric divisions. The balance between these two 
forms of division is controlled by developmental and environmental signals in order to 
produce appropriate numbers of stem cells and differentiated daughters (Morrison and 
Kimble, 2006). The combination of asymmetric and symmetric cell divisions to repair 
damaged adult tissue has recently been well described in muscle. 
In adult tissues such as muscle, satellite cells are the major source of myoblast 
generation during postnatal growth and after injury. When labeled satellite cells are 
engrafted, less than ten satellite cells can contribute to over 100 myofibres. In addition, 
these cells can self-renew after muscle lesion. Satellite cells have the ability to divide 
asymmetrically, and the frequency of asymmetric cell divisions increases after 24 hours 
when cells are seeded at higher cell densities and then declines significantly after 72 
hours (Shinin et al., 2006). 
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The descendants of activated satellite cells, called myogenic precursor cells, undergo 
multiple rounds of division prior to terminal differentiation and fusion to form 
multinucleated myofibers. Activated satellite cells also generate progeny that restore the 
pool of quiescent satellite cells (McKinnell et al., 2005). The molecular mechanism 
regulating self-renewal and differentiation suggests a combination of asymmetric and 
symmetric cell divisions in muscle satellite cells (Figure 4). 
Figure 4. Asymmetric division of stem cells generates self-renewing and committed 
cells.
Symmetric divisions generate either two self-renewing cells that are Pax7+/Myf5í (blue) 
or two committed cells that are Pax7+/Myf5+ (red). In adult skeletal muscle, symmetric 
divisions generate two identical (either stem or committed progenitor) daughter cells 
that both contact the basal lamina and the plasmalemma. Asymmetric division 
generates one self-renewing cell (Pax7+/Myf5í) that remains in contact with the basal 
lamina and one committed cell (Pax7+/Myf5+) that is adjacent to the plasmalemma but 
has lost contact with the basal lamina (from Cossu G. and et. al. 2007, with permission 
of Elsevier Limited). 
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Symmetric cell divisions in the muscle fiber (constituting 90% of all divisions) result in 
both daughters remaining in contact with the plasmalemma of the myofiber and the 
basal lamina, which includes the satellite cell. Notably, it is implied from the expression 
of the marker genes that these symmetric cell divisions can result either in the self-
renewal or the myogenic commitment of both daughter cells (Figure 4) (Cossu and 
Tajbakhsh, 2007). Evidence has also been provided for asymmetric cell divisions (10% 
of all divisions) that occur perpendicular to the muscle fiber (Kuang et al., 2007). These 
result in one daughter cell remaining in contact with the basal lamina and the other 
daughter cell losing this interaction but maintaining contact with the plasmalemma. The 
cell proximal to the plasmalemma expresses higher levels of Myf5, whereas the cell 
proximal to the basal lamina preferentially expresses Pax7 (Figure 4). This observation 
raises the intriguing possibility that the former will fuse with the fiber, whereas the 
latter will remain in the niche to generate other stem cells or re-enter quiescence (Cossu 
and Tajbakhsh, 2007). 
4.4.1.6  Adult MSC niche 
As described earlier, MSCs are now routinely isolated from the bone marrow of many 
mammalian model organisms, as well as from other tissues of mesodermal and non-
mesodermal origins. An interesting study has reported that plastic adherent MSCs 
derived from the brain, spleen, liver, kidney, thymus, lung, bone marrow, muscle and 
pancreas of mice all displayed similar morphologies and immunophenotypes in culture 
after several passages, but MSCs are not detected in peripheral blood. This study 
hypothesizes that the distribution of MSCs throughout the postnatal organism is related 
to their existence in a perivascular niche (da Silva et al., 2006). The data from current 
studies raise questions about the microenvironment of the MSCs, whether there is a 
common in vivo MSC niche in all of these tissues or whether MSCs function 
independently of their environments. 
Recently, the idea of a stem cell niche has gained wide support. Briefly, a niche 
includes all stem cells and their surrounding elements when they are in their naive state, 
including non-stem cells that might be in direct contact with them as well as ECM and 
soluble molecules found in that locale. These elements maintain the stem cells in their 
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undifferentiated state. It is then assumed that certain signals in the niche regulate the 
differentiation needed for regeneration or repopulation of a tissue (Li and Xie, 2005; 
Lin, 2002). However, the perivascular niche hypothesis describes the MSCs location in 
the basement membrane of blood vessels, throughout the body that gives them easy 
access to all tissues and provides stem cells to heal many different tissues (da Silva et 
al., 2006). Cellular, soluble and ECM components that are important in stem cell 
biology are involved in the MSC niche. 
4.4.1.7  MSC homing and wound healing 
Another stem cell niche related event is the homing of stem cells to sites of injury and 
subsequent wound healing. Signaling to progenitors or stem cells to home to the site of 
injury and differentiate into the required cell type is needed. To understand the niche, it 
is important to analyze not only what keeps stem cells in their niche but also what 
signals them to immigrate from it. The homing capacity of MSCs seems to be related in 
part to the expression of Stro-1. Stro-1 negative cells were better able to aid in the 
engraftment and survival of HSCs, whereas Stro-1 positive cells were more capable of 
homing and engrafting to most of the tissues studied (Bensidhoum et al., 2004). In the 
mouse, irradiation of both the whole animal and specific sites caused injected MSCs to 
engraft to more organs and in higher numbers than in unconditioned mice (Francois et 
al., 2006). It is known that injury alters the patterns of migration and differentiation of 
exogenously added MSCs. However, injected MSCs are capable of specific migration to 
the site of injury, influencing the idea of using these cells for therapeutic use (Barry and 
Murphy, 2004). 
4.4.1.8  Immunobiological characteristics  of adult MSCs 
Recent studies, mostly from in vitro experiments, show that MSCs contain attractive 
immunobiological properties. MSCs can evade immune recognition and inhibit the 
immune response. 
Adult MSCs express HLA class I, but not HLA class II on the cell surface. After 
36
differentiation into bone, cartilage, or adipose tissue, adult MSCs continued to express 
HLA class I, but not class II (Le et al., 2003). Cell surface expression of HLA class II 
can be induced in culture by treatment with IFN-J. After induction by IFN-J to express 
HLA class II, MSCs still escape recognition by alloreactive T cells (Gotherstrom et al., 
2004; Le et al., 2003). FAS ligand or costimulatory molecules, such as B7-1, B7-, CD40 
or CD40L, which are necessary for the T cell response, are not expressed by MSCs (Tse 
et al., 2003). MSCs failed to elicit a proliferative response when cocultured with 
allogeneic peripheral blood mononuclear cells (PBMC), despite provision of a 
costimulatory signal delivered by an anti-CD28 antibody and pretreatment of MSCs 
with IFN-J (Tse et al., 2003). 
MSCs also escape recognition by CTLs and alloreactive NK cells and inhibit the 
formation of cytotoxic T cells by secreting a soluble factor, but they do not interfere 
with CTL and NK cell lysis (Rasmusson et al., 2003). A recent study has revealed that 
MSCs remain resistant to CTL lysis, even after pulsing with specific synthetic peptide 
at high concentrations. MSCs induced CD25 up-regulation, although at relatively low 
levels, but were unable to induce CD3 or CD8 down-regulation at the surface of CTLs 
and also failed to induce IFN-J and TNF-Į production by CTLs (Rasmusson et al., 
2007). MSCs neither exhibited the humoral immune response in patients with prior 
hematopoietic stem cell transplantation nor did express any blood antigens (Sundin et 
al., 2007). 
The observations of these studies support the idea that MSCs may escape immune 
response and are capable to suppress immune reactions. This suggests that MHC-
mismatched MSCs may be utilized as universal donor cells for therapeutic purposes. 
However, implantation of murine MHC class I and class II- mismatched engineered 
MSCs for secretion of erythropoietin (Epo) led to robust and specific cellular immune 
responses in nonimmunosuppressed allogeneic mice (Eliopoulos et al., 2005), showing 
that in this model system, allogeneic immune responses could recognize and kill MSC. 
4.4.1.9  Immunomodulation of MSCs 
MSCs cocultured with purified CD19 positive B cells in the presence of a cocktail of 
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stimuli significantly inhibited B cell proliferation (Corcione et al., 2006). MSCs also 
inhibited professional antigen-presenting cells. MSCs cocultured with blood monocytes 
significantly inhibited the generation of differentiated dendritic cells, DCs, and MSCs 
cocultured with matured DCs caused a significant decrease in the expression of MHC 
class II molecules, CD80 and CD86 on DCs (Jiang et al., 2005). 
Ex vivo expanded MSCs have been shown to suppress the function of a broad range of 
immune cells, including T cells, B cells, NK cells and antigen-presenting cells. The 
mechanisms by which ex vivo expanded MSCs mediate immunosuppression have 
recently been studied. 
Soluble factors secreted by MSCs or immune cells in response to MSCs play a major 
role in MSC-mediated immune suppression. Soluble factors such as hepatocyte growth 
factor, prostaglandin E2, TGF-ȕ1, indoleamine 2,3-dioxygenase (IDO), nitric oxide and 
IL-10 have been demonstrated to be  involved, while other factors remain unknown 
(Tse et al., 2003; Djouad et al., 2003; Aggarwal and Pittenger, 2005; Beyth et al., 2005; 
Sato et al., 2007). Some studies reported that contact-dependent mechanisms might also 
be implicated, including the expression of B7H1 receptor on MSCs (Augello et al., 
2005; Krampera et al., 2003). Recent studies have shown that multiple 
immunosuppressive factors can be released by MSCs, and the nature of these factors 
varies depending on the nature of the stimuli received (e.g. allogeneic determinants, 
membrane-bound proteins, mitogens, and cytokines). In support of this, it has been 
observed that MSCs use different mechanisms to inhibit lymphocyte proliferation 
induced either by mitogens or alloantigens: the former, but not the latter, relying on the 
release of prostaglandins (Rasmusson et al., 2005). 
Cytokines play a crucial role in regulating MSC-mediated immunosuppression. Tumor 
necrosis factor (TNF)-Į can enhance the production of immunosuppressive 
prostaglandins by MSCs by as much as 100-fold (Aggarwal and Pittenger, 2005). IFN-Ȗ
is another important cytokine that regulates MSCs' immune functions. Studies have 
shown that IFN-Ȗ plays an active role in the immunosuppression mediated by MSCs 
(Chan et al., 2006; Krampera et al., 2006). IFN-Ȗ can induce MSCs to release 
prostaglandins and IDO (Aggarwal and Pittenger, 2005). IDO causes depletion of 
tryptophan, which is an essential factor for lymphocyte proliferation. However, it has 
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also been reported that IFN-Ȗ stimulates upregulation of MHC class I and II molecules 
on MSCs and induces MSCs to present antigenic peptides to CD4+ T cells (Stagg et al., 
2006).
4.4.1.10 Therapeutic application of MSCs 
MSCs have high expansion potential, genetic stability and can be easily collected and 
used. In addition, MSCs have two other extraordinary characteristics; they are able to 
migrate to sites of tissue injury and have strong immunosuppressive properties that can 
be exploited for successful autologous as well as heterologous transplantations (Le and 
Pittenger, 2005). GVDH is a form of rejection, in which transplanted cells begin to 
attack host tissues and organs. MSCs have been shown to have immunosuppressive 
properties and to delay skin graft rejection (Bartholomew et al., 2002; Di et al., 2002; 
Le and Pittenger, 2005). Moreover, MSCs produce cytokines that can support 
hematopoiesis and potentially enhance marrow recovery following chemotherapy or 
radiotherapy (Koc and Lazarus, 2001). 
Several studies have demonstrated that intracoronary injection of mixed populations of 
bone marrow stem cells or MSCs could represent a simple and successful approach to 
the treatment of heart diseases (Chen et al., 2004; Strauer et al., 2002). It has also been 
suggested that MSCs may be used to treat organ allograft rejection. Indeed, cardiac 
allograft studies have shown that MSCs home to the site of allograft rejection and 
participate in allograft tissue repair in the heart by giving rise to scar forming 
myofibroblasts and cardiomyocytes (Wu et al., 2003; Wu et al., 2005). 
MSCs have been shown to possess great somatic plasticity, since they are capable of 
differentiating into non-mesenchymal lineages. In fact, it has been demonstrated that 
MSCs are capable of differentiating into neurons and astrocytes in vitro and in vivo (Jori 
et al., 2005; Pittenger et al., 1999). Marrow stem cells have been shown to improve 
neurological performance in rats with brain ischemia. Moreover, MSC transplants delay 
the onset of neurological abnormalities and extend their lifespan (Zhao et al., 2002). 
These studies suggest that MSCs preferentially home to damaged tissue and have 
39
therapeutic potential. Possible clinical implications include therapy-resistant severe 
acute GVHD, treatment of organ allograft rejection and autoimmune disorders (Le, 
2006). MSC transplantation is also a form of cellular therapy with the potential for 
facilitating tissue repair both in inherited and acquired diseases. MSCs can be 
manipulated and differentiated into many different mesenchymal and non-mesenchymal 
lineages to produce functional cells. For example, tissue engineering for tendon, bone 
and cartilage repair is an exciting and realistic goal. MSC seems to be the superior 
candidates for cell therapy to regenerate injured skeletal tissues. 
In this thesis, we have also shown that MSCs are able to undergo chondrogenic 
commitment that is of great interest in articular cartilage engineering. In contrast to the 
ethical, immune response and the risk of teratoma formation of ESCs, MSCs lacks these 
limitations and are the suitable cells for therapeutic applications. 
4.4.2  Bone marrow MSCs 
Studies have demonstrated that bone marrow mesenchymal stem cells (BMMSCs) are 
true postnatal stem cells capable of differentiating into variety of cell types (Bianco et 
al., 2001). These cells were initially identified by their capacity to form clonogenic 
adherent cell clusters with fibroblastic morphology (Friedenstein et al., 1966). The 
maintenance and regulation of normally quiescent stem cell populations is tightly 
controlled by the local microenvironment according to the requirements of the host 
tissue. It is therefore critical to identify the locality of stem cells residing in different 
organs in order to further characterize the properties of stem cells with respect to their 
capacity for self-renewal and developmental potential (Shen et al., 2004). The recent 
identification of a putative perivascular niche for BMMSCs is a highlight in 
mesenchymal stem cell research (Bianco et al., 2001; Shen et al., 2004). BMMSCs can 
now be efficiently retrieved from bone marrow aspirates using various immunoselection 
protocols based on their high expression of the STRO-1 antigen (Dennis et al., 2002). 
STRO-1 appears to be an early marker of different mesenchymal stem cell populations 
that is also expressed by perivascular cells in situ. Currently, it is possible to isolate 
highly purified BMMSCs from the bone marrow using STRO-1 in combination with an 
antibody directed toward vascular cell adhesion molecule-1 (VCAM-1/CD106) 
(Gronthos et al., 2003b) or MUC-18 (CD146) (Shi et al., 2002). It is anticipated that 
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more sophisticated immunoselection methods, using additional markers, may help to 
accurately identify and purify multipotential human BMMSCs following ex vivo
expansion. Isolation of BMMSCs was described in section 7.1.3 of this thesis. 
Although BMMSCs are capable of multidifferentiation, it appears that they are most 
readily encouraged to develop towards an osteogenic pathway. When cultured in the 
presence of mineral-forming inductive medium, BMSSCs show the capacity to form 
structurally distinctive mineralized deposits in comparison with other mineral-matrix-
forming postnatal stem cells, such as dental pulp stem cells (Gronthos et al., 2003a; Shi 
et al., 2002). The processes by which stem cells settle, differentiate and form tissue in 
adults do not accurately recapitulate what happens during development, where the 
environment into which they are introduced may not be as collaborative as that in 
normal development. One of the most striking characteristics of the xenogeneic 
transplantation system is that BMMSCs can support and organize hematopoietic 
marrow during the osteogenic process. This may represent a dynamic process whereby 
multipotential BMMSCs attempt to reconstruct the microenvironment from which they 
were derived (Kuznetsov et al., 1997b). Although the detailed mechanisms involved in 
the initiation and maintenance of the bone marrow organ have yet to be determined, 
recent studies provide evidence suggesting that basic fibroblast growth factor (bFGF) 
and matrix metalloproteinase 9 (MMP9) may contribute to BMMSC-mediated 
osteogenesis and BMMSC-organized hematopoietic marrow formation in vivo (Batouli 
et al., 2003). 
4.4.2.1  The role of MSCs in developmental processes in bone marrow  
MSCs present in BM are thought to give rise to cells that constitute the hematopoietic
microenvironment (Prockop, 1997). MSCs have been isolated from BM and various
tissues from humans and many other species, expanded in culture, and shown to 
differentiate into many lineages under defined conditions in vitro. In culture, MSCs 
produce a number of cytokines and ECM proteins and express cell adhesion molecules, 
all of which are involved in the regulation of hematopoiesis (Conget and Minguell, 
1999; Majumdar et al., 1998). They also support the development of hematopoietic 
colonies in vitro (Majumdar et al., 1998). 
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To assess the engraftment, spatial distribution and lineage commitment of MSCs as well 
as their roles in hematopoiesis in vivo, it has been shown that transplanted MSCs can 
integrate into the functional components of the hematopoietic microenvironment and 
that these MSC-derived cells appear to be actively involved in the maintenance of 
human hematopoiesis in mice (Muguruma et al., 2006). 
Inside the BM niche environment, interactions between BMMSCs and HSCs may 
determine the homeostasis of the BM environment. A recent study has demonstrated 
that subcutaneously transplanted human BMMSCs, using hydroxyapatite tricalcium 
phosphate (HA/TCP) as a carrier vehicle, are capable of organizing hematopoetic 
progenitors of recipient origin. This study has demonstrated that multiple lineages of 
hematopoetic cells, including myeloid, lymphoid, erythroid and hematopoetic 
progenitor cells in BMMSCs transplants were generated. Interestingly, mice receiving 
lethal total body irradiation (TBI) could be rescued by systemic transplantation of BM 
cells isolated from the BMMSCs transplants. BM cells isolated from BMMSCs 
transplants contain functional hematopoetic progenitor cells to engraft and support 
hematopoiesis in recipients (Miura et al., 2006). These results indicate that the 
BMMSC-organized BM niche system represents a unique hematopoetic progenitor 
resource.
4.4.3  Adipose tissue–derived adult stromal stem cells 
MSCs can usually be isolated from several organs, such as fetal liver, umbilical cord 
blood and bone marrow (Wagner et al., 2005; Kern et al., 2006); and paper II). Adipose 
tissue is a highly complex tissue and consists of mature adipocytes, preadipocytes, 
fibroblasts, vascular smooth muscle, endothelial cells, resident monocytes/macrophages 
and lymphocytes (Weisberg et al., 2003; Caspar-Bauguil et al., 2005; Xu et al., 2003). 
The stromal-vascular fraction (SVF) of the adipose tissue that is obtained immediately 
after collagenase digestion has become a great focus of stem cell research because it 
provides a rich source of multipotent adipose tissue-derived adult stromal/stem cells 
(ADASCs) (Katz et al., 2005; Zuk et al., 2002; and paper I). Comparative analysis of 
MSCs obtained from bone marrow, adipose tissue, and umbilical cord clearly show that 
ADASCs are not different with regard to morphology, immune phenotype, success of 
isolating MSC, colony forming and differentiation capacity (Izadpanah et al., 2006; 
Kern et al., 2006). 
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4.4.3.1  Isolation and characterization  of ADASCs 
Liposuction is one of the most popular cosmetic surgical procedures, yielding a large 
volume (up to 2 L) of adipose tissue. Adipocytes represent roughly two-thirds of the 
total cell number and more than 90% of the tissue volume (van, V et al., 2005) and the 
ratio of adipocytes to ADASCs is constant in humans, independent of body mass index 
(BMI) and age (van, V et al., 2003). ADASCs yield varies among patients and is 
affected by many factors including donor site and storage duration. It also depends on 
isolation methods such as duration of collagenase digestion (Aust et al., 2004; Bakker et 
al., 2004; von et al., 2004). Fibroblast-like ADASCs are morphologically similar to 
MSCs obtained from other tissues. Moreover, ADASCs have the capacity to 
differentiate into cells of mesenchymal origin, such as adipocytes, myocytes, 
chondrocytes, and osteoblasts (Kern et al., 2006; Zuk et al., 2002; Yamada et al., 2007) 
and paper I. Factors such as donor age, type (white or brown adipose tissue) and 
localization, type of surgical procedure, culture conditions, plating density and media 
formulation can influence both the proliferation rate and differentiation capacity of 
ADASCs. A comparative study has shown that ADASCs have the same cell surface 
marker expression and differential potential as described for BM-MSCs. Similarity 
between ADASC and BM-MSC were further supported by gene expression. Gene array 
analysis revealed that less than 1% of genes were differentially expressed. However, 
some characteristics such as colony frequency and maintenance of proliferating ability 
in culture seem to be superior in ADASC compared with BM-MSC (Lee et al., 2004). 
Selected populations with a CD45-CD34+CD105+CD31- phenotype from human SVF 
have been kept in continuous culture without loss in proliferation capacity for more than 
eight months (paper I), which is much longer than BM-MSC can be maintained in 
culture (Paper II). Human ADASCs express a functional autocrine fibroblast growth 
factor (FGF) loop that allows for maintenance of their self-renewal ability in vitro
(Zaragosi et al., 2006). 
Phenotypic analysis of human MSCs derived from adipose tissue, bone marrow and 
umbilical cord has revealed no phenotypic differences among the three stem cell groups 
when using a panel of 22 surface antigens. When cultured in the appropriate induction 
media, MSCs were confirmed to exhibit osteogenic and adipogenic differentiation 
capability unlike control fibroblasts (Wagner et al., 2005). Global gene expression 
analysis of these MSCs has shown 25 genes including fibronectin, ECM2, glypican-4, 
43
IDI, NFIB, HOXA5 and HOXB6 that were overlapping and upregulated in the MSC 
preparations. In contrast, several hundred expressed sequence tags were identified to be 
differentially expressed when comparing adipose-derived MSCs with bone marrow and 
umbilical cord MSCs (Wagner et al., 2005). In another comparative study, 24 genes 
were upregulated in adipose tissue-derived MSCs compared with BM-MSCs, and they 
describe the differential expression profile of eight surface marker proteins in these 
cells. According to data from this study, less than 1% of genes are estimated to be 
differentially expressed between ADASC and BM-MSC (Lee et al., 2004). The 
published data in the literature support the hypothesis that ADASC and BM-MSC 
originated from identical precursor cells (Lee et al., 2004). 
In the end, ADASCs possess a similar phenotype and gene expression profile to bone 
marrow stem cells (Zuk et al., 2002; Lee et al., 2004; Wagner et al., 2005). In addition 
to having the capacity for self-renewal and long-term growth, ADASCs are capable of 
differentiating into diverse cell types including adipocytes (Rodriguez et al., 2004; Zuk 
et al., 2002), osteoblasts (Zuk et al., 2002), chondrocytes (Huang et al., 2004; Zuk et al., 
2002; Betre et al., 2006) hepatocytes (Seo et al., 2005; Talens-Visconti et al., 2006; 
Talens-Visconti et al., 2007), myocytes (Rodriguez et al., 2005), cardiomyocytes 
(Yamada et al., 2007), neurons (Guilak et al., 2006; Zuk et al., 2002), endothelial cells 
(Cao et al., 2005) and epithelial cells (Brzoska et al., 2005). Thus, ADASC are not only 
increasingly accepted as real adult stem cells but are also considered to be superior to 
other types of stem cells for future clinical applications (Strem et al., 2005). Whereas 
bone marrow can only be obtained in limited quantity because of donor site morbidity, 
adipose tissue is easily obtained in abundance. 
4.5  Epigenetic modifications of gene expression 
Just as cells inherit genes, they also inherit a set of instructions that tells the genes when 
to become active, in which tissue and to what extent. Without this “epigenetic” 
instruction manual, existence of multicellular organisms would be impossible (Jenuwein 
and Allis, 2001). Epigenetic is defined as any heritable influence in the progeny of cells 
or individuals, on chromosome or gene function that is not accompanied by a change in 
DNA sequence. 
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The cell nucleus is the most prominent compartment in the eukaryotic cell. In this 
compartment, many essential cellular activities take place, such as genome replication, 
control of gene expression and transcription, processing of transcripts and DNA repair. 
The cell nucleus is also an extremely dynamic structure where many components tend 
to rapidly and transiently interact with each other, giving rise to a highly ordered 
compartment (Misteli, 2005). The double strand of DNA, a major component of 
chromatin, and therefore of the nuclear compartment, can undergo chemical 
modification in the form of cytosine methylation of cytosine-guanine dinucleotides 
(CpG). This biochemical modification does not alter the subjacent genetic information 
of the DNA molecule, and is considered to be an epigenetic mark in the genome (Fuks, 
2005).
Histones, which are small and highly conserved basic proteins, are found in the 
chromatin of all eukaryotic cells. Different types of core histones H2A, H2B, H3 and 
H4 are associated with DNA to form a nucleosome. Nucleosomes are the basic 
components of a chromosome, in which the DNA helix is wrapped around core 
histones. A nucleosome contains two copies of each of the core histones wrapped with a 
146-bp DNA to form the simple 'beads on a string' structure that is then folded into 
higher-order chromatin. Chromatin also contains various proteins that are required for 
its assembly and packaging as well as for DNA replication, DNA modification, histone 
modification, transcription, DNA repair and DNA recombination (Narlikar et al., 2002; 
Zhang and Reinberg, 2001). 
Chromatin is not uniform with respect to gene distribution and transcriptional activity. It 
is organized into domains, such as euchromatin and heterochromatin. Euchromatins are 
the lightly staining regions of the nucleus that generally contain decondensed, 
transcriptionally active regions of the genome. Heterochromatins are cytologically 
defined genomic components that contain repetitive DNA and some protein-coding 
genes that have different chromosomal architecture, transcriptional activity and 
replication timing. 
Histone modification seems to be a universal regulatory mechanism among eukaryotic 
organisms from yeast to human. DNA methylation, however, is less conserved, but is a 
common and rapidly evolving mechanism among higher eukaryotic organisms with 
more complex genomes. The principal of epigenetic mechanisms by which tissue-
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specific gene-expression patterns and global gene silencing are established and 
maintained are chromatin modification and chromatin remodeling. Chromatin 
modification includes processes such as DNA methylation and histone modification, 
acetylation, phosphorylation, methylation and ubiquitylation. Chromatin remodeling 
includes processes with transient changes in chromatin accessibility. (Bird, 2002; 
Jenuwein and Allis, 2001; Narlikar et al., 2002; Zhang and Reinberg, 2001). 
4.5.1  DNA methylation and histone modification 
DNA methylation, chromatin structure and gene silencing are interconnected in 
mammals. High levels of CpG methylation coincide with heterochromatic regions and, 
upon integration into the genome, in vitro methylated DNA was shown to associate with 
a repressed chromatin structure. Unmethylated CpG-island chromatin is enriched in 
hyperacetylated histones (Bird and Wolffe, 1999). The mechanisms underlying these 
observation and discoveries have suggested the `histone code` hypothesis. According to 
this hypothesis, histone modifications, acting alone or in specific combinations, provide 
binding platforms for chromatin-associated proteins that initiate or block gene 
transcription (Jenuwein and Allis, 2001). 
In mammalian cells, DNA methylation occurs predominantly at CpG and is catalyzed 
by important DNA methyltransferases (Dnmt1, Dnmt3a and Dnmt3b). DNA 
methylation regulates gene expression through several distinct mechanisms and can 
directly block transcriptional regulatory factors from binding to their target sequences, 
although regulation by such a mechanism in vivo is relatively rare. DNA methylation 
can also repress gene expression through several methyl-CpG-binding proteins 
(MECPs) that 'read' DNA-methylation patterns (Jenuwein and Allis, 2001; Bird, 2002; 
Bird and Wolffe, 1999). 
The modification of core histones at the lysine (K), arginine and serine residues that lie 
in their amino-terminal tails is far more complex, involving many histone-modification 
enzymes. For example, Lys9 (K9), 14, 18 and 23 of H3 and K5, 8, 12 and 16 of H4, 
together with lysines on H2A and H2B, can be acetylated; whereas K4, 9 and 27, Arg2, 
17 and 26 of H3, and K20 and Arg3 of H4 can be methylated. Histone acetylation and 
deacetylation have been shown to determine the transcriptional activity of chromatin 
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(Strahl and Allis, 2000). 
MECP2 is one member of a family of methyl-binding domain proteins with affinity for 
methylated CpG dinucleotides. Recent studies have suggested diverse roles for MECP2 
in chromatin dynamics. MECP2 associates with both histone deacetylase (HDAC) 
activity and histone methyltransferase activity that directs the silencing mark for histone 
H3, K9 (H3K9). Acetylation of H3K9 (H3K9ac) is a mark of active chromatin, while a 
reciprocal pattern of trimethylation of the same residue (H3K9m3) often correlates with 
repression (Jenuwein and Allis, 2001; Thatcher and Lasalle, 2006). 
A variety of modifications on the amino-tails of histones have been characterized, of 
which methylation of lysine residues has been thought to be particularly stable 
(Jenuwein and Allis, 2001). The consequence of lysine methylation can differ both 
according to which lysine residue is modified and also as to how many methyl groups 
are added where lysine residues can be mono-, di- or trimethylated. For example, 
methylation of histone H3 at K9 (H3K9) or K27 (H3K27) is generally correlated with 
transcriptional repression, whereas methylation at K4 (H3K4) is predominantly 
associated with transcriptional activity. In addition, the level of methylation is 
important, for example H3K9m3 shows a different distribution from H3K9m1 and 
H3K9m2 in mammals (Schubert et al., 2006). 
As a summary of the epigenetic terms used in this thesis, the transcription status of a
gene is affected by modifications of histones H3 and H4. Trimethylation of K9 of H3 
(H3K9m3), H3K27m1, and H4K20m3 has been shown to be part of constitutive 
heterochromatin and associated with long-term gene repression. Facultative 
heterochromatin, associated with loci that are temporarily inactive, is enriched in 
H3K9m2, H3K27m3 and H4K20m1. Both forms of transcriptional inactivation are also 
associated with H3K9 deacetylation. In contrast, di- or trimethylated H3K4, H3K36m3 
and H3K79m3, together with acetylated H3K9 (H3K9ac), mark a gene for transcription 
(Lachner and Jenuwein, 2002). Chromatin immunoprecipitation (ChIP) is a key 
technique used in paper III of this thesis for studying protein-DNA interactions and 
mapping epigenetic histone modifications on DNA (Dahl and Collas, 2007). 
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4.6  Articular cartilage 
The fields of tissue engineering and regenerative medicine have made enormous strides 
over the last decade. The final goal of tissue engineering should be functional recovery 
of damaged tissue in vivo. The development of cell-based treatment for cartilage repair 
requires a cell source that can efficiently produce and assemble a cartilage matrix. 
Chondral defects lack the capacity to regenerate new cartilage surfaces due to lack of 
vessels, nerve supply and isolation from systemic regulation. With full thickness 
articular injury, a healing response is initiated. This response usually produces collagen 
type I and generation of fibrous cartilage rather than the preferred hyaline. This, 
consequently, leads to a tendency for the development of osteoarthritis (Mandelbaum et 
al., 1998). 
Autologous chondrocyte implantation (ACI) using chondrocytes from patients was first 
described in 1994 (Brittberg et al., 1994) with encouraging results. A part of this thesis 
has focused on improvement of human articular chondrocyte (AC) expansion in vitro
for cartilage tissue repair. Some characteristics of cartilage and chondrocyte biology 
that are essential for understanding repair of damaged tissue are discussed in this 
section.
4.6.1  Joint 
Joints are structures in the body that provide movement and mechanical support. There 
are several types of joints. The focus of this part of my thesis is on synovial joints, such 
as those in the knees and shoulders. These joints, found at the ends of bones, have a 
space that allows for a wide range of motion. Joints are strengthened by a dense fibrous 
capsule reinforced with ligaments and muscles. The joint space is filled with synovial 
fluid, a lubricant that also provides nutrients to the joint tissues. The bony surfaces 
within synovial joints are covered with articular cartilage (Clark, 2007). 
4.6.2  Structure and functional properties of articular cartilage 
Articular cartilage consists of four layers of tissue. First, a thin superficial layer 
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provides a smooth surface for two bones to slide against each other. The second layer is 
very resistant to shear stresses. An intermediate layer is mechanically designed to 
absorb shock and distribute load or weight efficiently. The fourth or deepest layer is 
highly calcified and anchors the articular cartilage to the bone (Clark, 2007). 
The most important function of articular cartilage is its ability to support large loads 
during motion. This functionality has been attributed to its highly organized ECM. 
Chondrocytes, the cell type found in articular cartilage, are responsible for the 
production, organization, and maintenance of the articular cartilage ECM, and are, 
therefore, ultimately responsible for the integrity of the cartilage (Chen et al., 2006). 
Articular cartilage ECM contains a fluid phase of water (68-85% of total weight) and a 
solid, organic phase of ECM proteins. Interstitial fluid support can account for more 
than 90% of the load-bearing capacity of the joint. The articular cartilage ECM 
comprises three classes of proteins: collagen type II (60-86% of dry weight), 
proteoglycans (15-40% of dry weight) and quantitatively minor components, such as 
collagen type IX, XI, V and other noncollagenous proteins including link protein, 
fibronectin and cartilage oligomeric matrix protein. In addition it also contains smaller 
proteoglycans, biglycan, decorin and fibromodulin, which also have important roles in 
controlling matrix structure and organization (Figure 5). 
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Figure 5. Extracellular matrix of cartilage.
Three classes of proteins exist in articular cartilage: collagens (mostly type II 
collagen); proteoglycans (primarily aggrecan); and other noncollagenous proteins 
(including link protein, fibronectin, cartilage oligomeric matrix protein) and the smaller 
proteoglycans (biglycan, decorin and fibromodulin). The interaction between highly 
negatively charged cartilage proteoglycans and type II collagen fibrils is responsible 
for the compressive and tensile strength of the tissue, which resists load in vivo. 
Abbreviation: COMP, cartilage oligomeric matrix protein (from Chen FH. and et. al. 
2006, with permission of Nature Publishing Group). 
The ability of articular cartilage to resist compression is primarily a result of the 
presence of large proteoglycan aggregates, termed aggracan. Aggrecan monomers 
consist of a core of protein and keratin sulfate glycosaminoglycan (GAG) chains, filling 
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the interstices of the collagen meshwork by forming large aggregated complexes 
interacting with hyaluronic acid (HA) and link proteins (Nagase and Kashiwagi, 2003). 
HA is a GAG with repeated disaccharide units of D-glucuronic acid and N-acetyl-D-
glucosamine connected by ȕ-linkages (Tanimoto et al., 2004), playing an essential role 
in the structural organization and function of cartilage, cell adhesion, migration and 
differentiation mediated by HA-binding proteins and cell surface receptors such as 
CD44 (Knudson and Knudson, 1993; Laurent and Fraser, 1992). The high density of 
fixed negative charges of the sulfated GAG chains of proteoglycans draws water into 
the cartilage, resulting in high osmotic pressure, which is restrained by the collagen 
network, thus giving rise to the compressive behavior of cartilage. The tensile resilience 
and strength of cartilage, on the other hand, is imparted primarily by the network of type 
II collagen fibers. Overall, the interaction between collagen type II, aggrecan, link 
protein and HA provides cartilage with its ability to resist compressive loads. The 
biomechanical properties of articular cartilage thus depend largely on the maintenance 
of high proteoglycan and collagen contents within the matrix, which represent the 
current standard for measuring the functionality of engineered cartilage constructs 
(Chen et al., 2006). 
4.6.3  Chondrogenesis 
Chondrogenesis is a process that results in the formation of the cartilage intermediate 
(anlagen) and leads to endochondral ossification during skeletal development, which is 
essential for proper formation of endochondral bones. The vertebrate skeleton, 
composed of cartilage and bone, is the product of three distinct embryonic lineages. The 
craniofacial skeleton is formed by cranial neural crest cells, the axial skeleton is derived 
from paraxial mesoderm (somites) and the limb skeleton is the product of lateral plate 
mesodermal cells. Cells in these lineages migrate to the locations in the embryo where 
skeletal elements will develop, form characteristic mesenchymal condensation of high 
cell density and differentiate to osteoblasts or chondrocytes (Olsen et al., 2000). 
In the human embryo, the appendicular skeleton develops from limb buds that are first 
visible at around 4 weeks of gestation. Subsequent stages of human limb development 
are divided into formation of the cartilaginous anlagen that shapes skeletal elements and 
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subsequently results in joint formation. The joint develops from the primitive avascular, 
densely packed cellular mesenchyme termed the skeletal blastema. The skeletal 
elements are prefigured in mesenchymal condensations, and common precursor 
mesenchymal cells divide into both chondrogenic and myogenic lineages that determine 
the central differentiation of cartilage and peripheral differentiation of muscle. The 
surrounding tissues, particularly the epithelium, influence the differentiation of 
mesenchymal progenitor cells to chondrocytes. Cartilaginous nodules appear in the 
middle of the blastema and, simultaneously, cells at the periphery become flattened and 
elongated to form the perichondrium. The differentiated chondrocytes can then 
proliferate and the complex process of hypertrophic maturation occurs (Goldring et al., 
2006; Pacifici et al., 2006). The different stages of chondrogenesis are briefly described 
below.
(A)
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(B)
Figure 6. Sequence of events of chondrogenesis until the development of long bones.
A: The different stages are represented schematically, showing the temporal patterns of 
growth and differentiation factors (above the arrows) and the transcription factors 
involved below the arrows. The extracellular matrix proteins that distinguish the 
different stages are indicated below. B: Schematic representation of the expression of 
transcriptional regulators at different stages of chondrogenesis and endochondral 
ossification. Additional transcription factors that are inhibitors or activators at different 
stages are indicated below the scheme of cellular transitions (from Goldring MB. and 
et. al. 2006, with permission of Wiley-Liss, Inc. a subsidiary of John Wiley & Sons, 
Inc.).
4.6.3.1  Mesenchymal cell condensation 
Chondrogenesis is the earliest step of skeletal development.  It is initiated by the 
migration of mesenchymal cells to the site of future skeletogenesis, followed by 
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proliferation. The next step is the tissue (epithelial-mesenchymal) interaction that results 
in condensation and differentiation to chondroblasts or osteoblasts. Each phase involves 
different cellular processes and separate gene expression patterns (Figure 4A) (Hall and 
Miyake, 2000). Prior to condensation, the prechondrocytic mesenchymal cells produce 
ECM that is rich in hyaluronan and collagen type I, as well as collagen type IIA 
containing the exon 2 encoded amino acid propeptide found in neocartilage collagens 
(McAlinden et al., 2005). The initiation of condensation is associated with increased 
hyaluronidase activity and the appearance of the cell adhesion molecules neural 
cadherin (N-cadherin) and neural cell adhesion molecule (N-CAM). TGF-ȕ, which is 
among the earliest signals in chondrogenic condensation, stimulates the synthesis of 
fibronectin, which in turn regulates N-CAM. Syndecan binds to fibronectin and 
downregulates N-CAM, thereby setting the condensation boundaries. The ECM 
molecules, which also include tenascins and thrombospondins,  as well as cartilage 
oligomeric protein (COMP), interact with the cell adhesion molecules to activate 
intracellular signaling pathways involving focal adhesion kinase and paxillin, to initiate 
the transition from chondroprogenitor cells to a fully committed chondrocyte (DeLise et 
al., 2000). N-cadherin and N-CAM disappear in differentiating chondrocytes and are 
later detectable only in perichondrial cells (Goldring et al., 2006). 
4.6.3.2  Chondrocyte differentiation
Investigations of cartilage development explain the differentiation of 
chondroprogenitors for subsequent stages of skeletogenesis. The nuclear transcription 
factor Sox9, one of the earliest markers expressed in cells undergoing condensation 
(Figure 5A and 5B), is required for the expression of the type II collagen gene 
(COL2A1) and certain other cartilage-specific matrix proteins, including collagen XIA2 
(Col11a2) and cartilage-derived retinoic acid-sensitive protein (CD-RAP) genes, prior 
to matrix deposition in the cartilage anlagen, reviewed in (Goldring et al., 2006). Two 
additional Sox family members, L-Sox5, a long form of Sox 5, and Sox6 are co-
expressed with Sox9 during chondrocyte differentiation (Lefebvre et al., 2001). L-Sox5 
and Sox6 are required for the expression of Col9a1, aggrecan and link protein, as well 
as Col2a1, during chondrocyte differentiation (Smits et al., 2001) (Figure 5A). The 
effect of BMP signaling on chondrogenic differentiation is mediated through Sox9, L-
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Sox5 and Sox6 regulation via their receptors, BMPR1A (ALK-3) and 1B (ALK-6) 
(Yoon et al., 2005). The runt-domain transcription factor, Runx2 (also known as core 
binding factor, Cbfa1 and Osf2), is expressed during the condensation stage of 
chondrogenesis, chondrocyte maturation and osteoblast differentiation. Sox9 and Runx2 
are coexpressed during mesenchymal condensation and dominance of Sox9 function 
over Runx2 during this early first step in progenitor cell fate determines between 
osteoblastic and chondrogenic lineages (Zhou et al., 2006) (Figure 4A and 4B). 
4.6.3.3  Chondrocyte proliferation 
 Chondrocytes mature towards two different fates after commitment to the chondrogenic 
lineage; they remain as chondrocytes (persistent cartilage) or differentiate to 
hypertrophic chondrocytes (transient cartilage). The chondrocytes that stop 
differentiating form the persistent cartilage located on the articular surfaces of joints. 
These chondrocytes do not differentiate further or mineralize their ECM. Chondrocytes 
that continue to differentiate to the hypertrophic state proliferate and contribute to the 
formation of the growth plate, reviewed in (Woods et al., 2007). 
Hypertrophic differentiation starts from the center of the cartilage element where 
chondrocytes undergo a multistep program, differentiating into prehypertrophic, 
hypertrophic and, finally, terminal hypertrophic chondrocytes. The region of terminally 
differentiated chondrocytes is subsequently invaded by blood vessels followed by 
osteoclasts and osteoblasts, which start to replace cartilage with bone and bone marrow. 
The interactions of fibroblast growth factor (FGF), Indian hedgehog/parathyroid 
hormone-like peptide (Ihh/Pthlh) and BMP signaling integrates chondrocyte 
proliferation and hypertrophic differentiation (Minina et al., 2002) (Firures 5A and 5B). 
Throughout chondrogenesis, the balance of signaling by BMPs and FGFs determines 
the rate of proliferation, thereby adjusting the rate of differentiation. Whereas FGF 
signaling accelerates the rate of terminal hypertrophic differentiation, BMPs have been 
shown to hinder this process. The proliferation of chondrocytes in the lower 
proliferative and prehypertrophic zones is also under the control of a local negative 
feedback loop involving signaling by Pthlh and Ihh. By simultaneously regulating 
proliferation, Ihh expression and the rate of terminal hypertrophic differentiation, the 
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balance of FGF and BMP signals seems to adjust the process of hypertrophic 
differentiation to the proliferation rate (Minina et al., 2002). 
4.6.3.4  Growth plate and chondrocyte hypertrophy 
Longitudinal bone growth occurs at the growth plate, a thin cartilage structure situated 
at the end of tubular bones, by a process called endochondral ossification, in which 
cartilage is formed and then remodeled into bone tissue. The growth plate consists of 
three principal layers: the resting zone close to the epiphysis, the proliferative zone in 
the middle and the hypertrophic zone close to the metaphysis. The newly formed 
cartilage is invaded by blood vessels and bone cell precursors, which remodel the 
hypertrophic zone cartilage into bone. 
The growth plate contains one cell type, the chondrocyte, at different stages of 
differentiation. Resting zone chondrocytes replicate at a slow rate (Kember, 1971) and 
act as stem-like cells that refill the pool of proliferative chondrocytes (Abad et al., 
2002). Proliferative zone chondrocytes replicate at a high rate (Kember, 1971), and the 
resulting daughter cells line up along the long axis of the bone. As a result, 
chondrocytes are arranged in columns parallel to this axis, a process critical for the 
formation of bones with an elongated shape (Abad et al., 2002). At a certain point, the 
cells stop dividing and terminally differentiate into hypertrophic chondrocytes. 
Hypertrophic chondrocytes undergo apoptosis shortly before vessels invade the 
chondrocyte lacuna (Gerber et al., 1999; Goldring et al., 2006). Chondrogenesis 
resulting in cartilage formation is regulated by numerous complex interactions. 
Understanding these regulative processes is essential for cartilage tissue engineering. 
4.6.4  Chondrocyte response to mechanical loading and degeneration of cartilage 
The unique biomechanical properties of healthy cartilage ensure that articular cartilage 
is able to transmit force between the joints while maintaining almost friction-free limb 
movement. Human articular cartilage experiences a wide range of stress during normal 
joint loading. Stresses in the range of 300-800% of body weight are normal in the hip, 
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but above this physiological range compression of cartilage causes deformation of cells 
and matrix, gradients in hydrostatic pressure, intratissue fluid flow and associated 
electrokinetic effects (e.g., flow-induced streaming potential). The deformation of the 
charged ECM will change the ionic concentration, osmolarity and pH of the cellular 
environment of the cartilage. Tissue fluid flow during loading can also dramatically 
enhance transport of nutrients and macromolecules such as growth factors and 
cytokines. Therefore, mechanical and chemical changes during loading can alter 
chondrocyte behavior and, as a result, matrix synthesis and turnover (Kerin et al., 2002). 
4.6.5  Repair of articular cartilage 
Recent and more advanced understanding of how the articular cartilage was formed 
during development and how the adult articular chondrocytes function within their 
unique environment will enable us to control further development of cartilage diseases 
at early stages or plan repair strategies for damaged cartilage. Lesions are generated 
during the course of many joint diseases, especially during osteoarthritis (OA), a 
number of genetic or metabolic conditions and/or as a result of trauma. Traumatic 
lesions may occur directly or indirectly as a result of the strength of mechanical loading 
or following ligament injuries (Newman, 1998). The capacity of adult articular 
chondrocytes to repair lesions and regenerate the normal cartilage matrix is limited and 
the damage becomes irreversible unless the destructive process is interrupted (Goldring, 
2006).
Numerous experimental and clinical attempts have been made to repair articular 
cartilage lesions or at least to bring symptomatic relief. In fact, relief of symptoms and 
improvement in functionality are the main reasons for performing these procedures. 
These techniques can be divided into four categories: (1) symptomatic treatment: 
lavage, shaving and debridement; (2) stimulation of bone marrow derived cells: drilling, 
microfracture, abrasion and deep abrasion (spongiolization); (3) transplantation of 
osteochondral plugs: allografting and autografting (mosaicplasty), and (4) 
chondrogenesis within transplanted cells/tissue: periosteal grafting, autologous 
chondrocyte implantation (ACI). Of these techniques, only the strategy involving 
transplantation of cells will be further described in this thesis. 
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4.6.5.1  Autologous chondrocyte implantation (ACI) 
ACI falls within the group of therapies that aim to induce chondrogenesis within 
transplanted cells or tissues. The ability to harvest a sufficient number of autologous 
primary chondrocytes is the first step. Material is derived from the patient’s own 
cartilage, from non-load bearing areas of healthy regions of hyaline cartilage. The 
cartilage biopsies are around a few hundred milligrams in weight. Cell isolation 
procedures rely on enzymatic digestion of the cartilage tissue, followed by in vitro
expansion of the chondrocytes in adherent, monolayer cell cultures. In the second step, 
the chondral lesion is surgically prepared and covered with a periosteal flap, which is 
sutured to the surrounding cartilage tissue. The cultured chondrocytes, now in single 
cell suspension, are then injected beneath the flap, which is peripherally sealed with 
biological fibrin glue (Brittberg et al., 1994). 
The first study describing repair of human osteochondral defects by transplantation of 
cultured chondrocytes was reported in 1994 (Brittberg et al., 1994). Since then, several 
studies using autologous chondrocyte implantation (ACI) have described good or 
excellent results for the majority of patients (Peterson et al., 2003; Recht et al., 2001). 
Although ACI is a safe technique, other reports are not as positive and their available 
data are not supportive of its being more effective than other therapeutic strategies in 
the treatment of chondral lesions of the knee (Jakobsen et al., 2005; Hunziker, 2002; 
Giannoni and Cancedda, 2006; Hambly et al., 2006; Ruano-Ravina and Jato, 2006). 
However, ACI is a procedure which may be further improved using various tissue 
engineering techniques. Obviously, transfer of a chondrocyte from its 3D native 
environment to a 2D monolayer proliferative condition results in a generally diminished 
chondrogenic potential of the expanded cells. Adhesion to a two-dimensional surface 
seems to be a prerequisite for chondrocyte proliferation. In the course of adhesion and 
proliferation, the cells alter their morphology and metabolism in a process known as 
dedifferentiation (Schnabel et al., 2002). The gene expression profile of the cells is 
profoundly altered, and the metabolic activity of the dedifferentiated chondrocytes is 
directed mainly towards proliferation. Endogenous production of collagen type II and 
aggrecan is significantly reduced and predominately replaced by collagen type I and 
versican (az-Romero et al., 2005; Fuss et al., 2000; Stewart et al., 2000). The tissue 
repair resulting from transplantation of dedifferentiated chondrocytes is often 
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fibrocartilaginous (Darling and Athanasiou, 2005a; Tins et al., 2005). These topics will 
be discussed further in paper III of this thesis. 
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5.  AIM OF THE STUDY 
The overall purpose of this study was to establish optimal expansion protocols for cells 
of potential use in regenerative medicine, and to use different strategies to carefully 
characterize these cells. 
The specific aims of the present study were: 
1) To isolate sufficient human stromal stem cells from adipose tissue (ADASC) 
and purify and characterize uncultured and cultured expanded cells to investigate their 
phenotype and global gene expression. 
2) To investigate if autologous serum (AS) or allogeneic human serum (alloHS) 
could replace FBS for the expansion of hMSCs in vitro.
3) To determine if human articular chondrocytes (AC) may be expanded in vitro
to therapeutically useful numbers without losing collagen type II synthesis and 
sercretion.
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6.  SUMMARY OF THE PAPERS 
Paper I: 
Isolation and transcription profiling of purified uncultured human stromal stem 
cells: Alteration of gene expression after in vitro cell culture.
Freshly isolated stromal stem cells have been too few or insufficiently pure to be 
thoroughly characterized as uncultured progenitors. Most of our current knowledge 
about these cells is based on their expansion in vitro. In this study, we showed that 
freshly isolated cells from human adipose tissue with CD45-CD34+CD105+CD31-
phenotype are the precursors from which multilineage cells are derived. These 
precursors, compared with another isolated population having a CD31+ phenotype, 
overexpressed transcripts associated with cell cycle quiescence and stemness, and 
transcripts involved in the biology of cartilage, bone, fat, muscle and neural tissues. In 
contrast, CD31+ cells overexpressed transcripts associated with endothelium and major 
histocompatibility complex class II.  
CD31+ cells did not proliferate in vitro, but CD31- cells proliferated and could be 
differentiated to cells with characteristics of bone, fat, cartilage and neural-like tissue. 
Upon culture, transcripts associated with cell cycle quiescence, stemness, certain 
cytokines and organ specific genes were downregulated, whereas transcripts associated 
with signal transduction, cell adhesion, and cytoskeletal components were upregulated.  
Thus, the CD45-CD34+CD105+CD31- population from adipose tissue contains cells 
with great potential for therapeutic tissue regeneration. 
Paper II:
In Vitro expansion of human mesenchymal stem cells: Choice of serum is a 
determinant of cell proliferation, differentiation, gene expression and 
transcriptome stability.
In this study, we have investigated the possibility of using autologous serum (AS) or 
allogeneic human serum (alloHS) rather than FBS for in vitro expansion of (hMSCs) for 
cell therapy and tissue engineering purposes. We found that the choice of serum 
affected hMSCs at several different levels. hMSCs expanded in AS proliferated faster 
but differentiated more slowly toward mesenchymal lineages than hMSCs expanded in 
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FBS. Changes in gene expression reflected these differences. The use of alloHS resulted 
in hMSC growth arrest and death. Genome-wide microarray analysis identified 
transcripts involved in the cell cycle and differentiation that was differentially regulated 
between hMSCs in FBS and AS. Finally, several transcripts, including some involved in 
cell cycle inhibition, were upregulated in hMSCs in FBS at late passages, while the 
hMSC transcriptome in AS was remarkably stable.  It seems that FBS induces a more 
differentiated and less stable transcriptional profile, whereas hMSCs may be expanded 
rapidly with stable gene expression in AS in the absence of growth factors. This insight 
may be useful for protocols where hMSC are to be used for cellular therapy. 
Paper III:
Persistent collagen type II synthesis and secretion in rapidly proliferating human 
articular chondrocytes in vitro.
In this study, we investigated whether human articular chondrocytes (hAC) may be 
expanded in vitro to therapeutically useful numbers without losing collagen type II 
synthesis and secretion. hAC were expanded in vitro adherent to plastic or supported by 
their own ECM in loose structures called chondrocytes in autologous  ECM (CA-ECM). 
Real-time PCR, flow cytometry and electron microscopic immunogold techniques were 
used to determine the presence of key molecules of hyaline cartilage ECM. Promoter 
methylation and histone modification studies were performed to assess epigenetic 
mechanisms underlying chondrocyte dedifferentiation. Plastic adherence quickly led to 
loss of collagen type II production. Culturing hAC as CA-ECM allowed the 
chondrocytes to remain attached to their own ECM. Here, hAC maintained a rounded 
shape, proliferated rapidly and continued to synthesize and secrete collagen type II. This 
was associated with high levels of Sox9 mRNA expression. Collagen type I was found 
at the mRNA and intracellular protein level, but not in the ECM. Epigenetic changes 
could not account for the variations in collagen type II production observed in this 
study.
Supported by their own ECM in CA-ECM, hAC proliferate to clinically useful numbers 
while maintaining collagen type II synthesis and secretion. In vitro expansion of high 
numbers of collagen type II secreting chondrocytes may improve tissue engineering of 
joint surfaces. 
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7.  METHODOLOGICAL ASPECTS
7.1  Isolation and culture of cells 
7.1.1  Isolation of the SVF from human adipose tissue and isolation of ADASC 
from SVF 
The SVF was separated from adipose tissue using a modified procedure (Zuk et al., 
2001). Washed adipose tissue was digested with collagenase. Red blood cells were 
removed from SVF pellets by lysis buffer and suspended cells were passed through 100-
ȝm and then 40-ȝm cell sieves. Cell suspensions were applied to Histopaque gradients 
and interfaces were collected, washed in buffer solution and passed through a 30-ȝm
mesh. Cell counts and viability assessment were performed. SVF analysis by flow 
cytometry revealed a haematopoietic CD45+ population. SuperMACS magnetic beads 
coupled to anti-human MAb were used to remove CD45+ cells from SVF according to 
the instructions provided by the manufacturer. Remaining CD45- cells contained CD31+
and CD31- populations which were separated by superMACS. Cells were incubated 
with fluorescein isothiocyanate (FITC)-conjugated mouse anti-human CD31 MAb. 
After washing, antibody-coated cells were incubated with anti-FITC microbeads. 
Microbead-coated CD31+ cells were retained in LS columns, allowing for initial 
isolation of CD31- cells. Later, CD31+ cells were separately flushed out of the columns. 
Flow cytometry was used to confirm separation, and purity was less than 8% 
contaminating cells in both populations. 
7.1.2  Culture of isolated human ADASC 
After isolation, CD31+ and CD31- cell subsets and clonal cell lines were cultured in 
DMEM/F12 containing 20% FBS, antibiotics and amphotericin B (culture medium) at 
37°C in an atmosphere of 5% CO2 in humid air. After one week, attached cells were 
passaged by trypsin-EDTA and cultured in DMEM/F12 containing 10% FBS without 
amphotericin B. Clonal cell lines from CD31- cells were achieved by culturing single 
fresh cells in separate wells. Using a micropipette, a single cell was placed into each 
well of 48-well plates containing culture medium. Colony-forming ability was assessed 
after 3 weeks. At that time, colonies were passaged and cultured further in DMEM/F12 
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containing 10% FBS without amphotericin B. 
7.1.3  Isolation and culture of human bone marrow MSCs 
Bone marrow was obtained from the human iliac crest and the aspirate was diluted in 
DMEM/F12 medium. Mononuclear cells were separated from the interface after 
performing density-gradient centrifugation. Since mononuclear cells cultured in AS but 
not in FBS were always contaminated with a plastic attached CD14+ monocyte 
population, CD14+ cells were removed using magnetic beads coupled to mouse anti-
human CD14 monoclonal antibody MAb, superMACS magnet and LS columns. CD14–
cells were washed and allowed to adhere overnight at 37°C with 5% humidified CO2 in 
five parallel flasks. Each flask contained DMEM/F12 medium supplemented with 
antibiotics, amphotericin B and 20% serum from one of the following sources: FBS 
from 3 different sources, a human commercially available off the clot pooled allogeneic 
serum and autologous serum. After 24 hours, nonadherent cells were discarded and 
adherent cells were washed with PBS and then cultured in DMEM/F12 medium with
antibiotics and 20% of the same serum. At approximately 50% confluence, the cells 
were suspended using trypsin-EDTA and replated at approximately 5,000 cells per cm2.
The preferred cell seeding density and cell culture confluency gave rise to optimal cell 
growth for non-differentiated cell conditions. After the first passage, amphotericin B 
was removed and 10% instead of 20% serum was used for further cell cultures. Viable 
cells were counted at each passage. 
7.1.4  Isolation and culture of human articular chondrocytes 
Human articular cartilage was obtained from a low-load bearing area on the proximal 
part of the lateral femoral condyle of the injured knee for autologous chondrocyte 
implantation (ACI) cultures or from the lateral femoral notch of patients undergoing 
anterior cruciate ligament (ACL) surgery for in vitro studies. In all cases informed 
consent was obtained, and the study was approved by the Regional Committee for 
Ethics in Medical Research. The biopsies were digested in two different ways: in the 
single cell procedure, biopsies were minced and digested by collagenase type XI and 
deoxyribonuclase I at 37ºC in room air with 5% CO2 for 3-5 hours. The digested 
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biopsies were then filtered through 70 ȝm cell strainers. The resulting single cells were 
resuspended in culture medium supplemented with antibiotics, amphotericin B, ascorbic 
acid and 20% AS. 
In the CA-ECM procedure, biopsies were minced to very tiny pieces and then digested 
in collagenase type XI at 37ºC in room air with 5% CO2 for 90 minutes. The structures 
formed by this procedure, called CA-ECM, were washed and resuspended in culture 
medium supplemented with 20% AS. In some experiments, single AC from each of the 
three donors was established in monolayer cultures (see paper III). In other experiments, 
CA-ECM from other donors was established in 3D cultures at 37º C in room air with 
5% CO2, incubator atmosphere. At the first passage, or the medium change at 8-9 days 
of culture, amphotericin B solution was removed and 10% AS was used instead of 20% 
in the culture medium. For each passage, cells were detached from the plastic surface or 
released from CA-ECM with trypsin-EDTA, and viable cells were counted. 
7.2  Preparation of autologous serum 
Whole blood was quickly transferred to 10-ml vacutainer tubes without anticoagulants
and allowed to clot for 4 hours at 4°C to 8°C. Subsequently, the blood was centrifuged
at 1800g at 4°C for 15 minutes. Serum was collected and filtered through a 0.2-μm 
membrane. Aliquots of the sterile autologous serum (AS) were stored at –20°C. 
7.3  Flow cytometry 
Freshly isolated and cultured cells were examined for surface and intracellular molecule 
expression using flow cytometry. MAbs conjugated to fluorecein isothiocyanate (FITC), 
phycoerythrin (PE), Peridinin chlorophyll protein (PerCP), cyanine dye (CY) and 
allophycocyanin (APC) fluorochromes were used. Irrelevant control MAbs were 
included for all fluorochromes. Cells were coated with directly conjugated MAbs, 
washed, and fixed in 1% paraformaldehyde. Cells were also stained with unconjugated 
MAbs directed against the cell surface antigens. Cells were incubated with primary 
MAbs, washed and incubated with PE-conjugated goat anti-mouse secondary 
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antibodies. Cells were then washed, fixed in 1% paraformaldehyde and analyzed. For 
detection of intracellular proteins, cells were fixed in 1% paraformaldehyde for 4h and 
incubated overnight with 1% Tween-20. For immunolabeling, cells were then incubated 
with primary MAbs, washed, and incubated with PE-conjugated goat anti-mouse 
secondary antibodies. Cells were washed, fixed in 1% paraformaldehyde and analyzed 
using a FACSCalibur flow cytometer. Gates were set based on staining with 
combinations of relevant and irrelevant MAbs so that no more than 1% of cells stained 
with irrelevant antibodies were positive. 
7.4  Real-Time quantitative RT-PCR 
Total RNA was extracted from cell pellets using Trizol. Following treatment with 
DNase I, reverse transcription (RT) was performed according to the manufacturer’s 
protocol (Invitrogen, Carlsbad, CA) with 100 ng total RNA per RT reaction. All assays 
were designed to overlay a junction between two exons to avoid hybridization to 
genomic DNA. 18S was included as an endogenous normalization control. 
Quantification of cDNA was performed using the 7300 Real Time PCR system 
(Applied Biosystems). Gene expression was calculated using the relative standard curve 
method (User Bulletin 2, Applied Biosystems). 
7.5  Microarray analysis 
 RNA sample preparation and microarray assays were performed according to the 
Affymetrix GeneChip Expression Analysis Technical Manual (Affymetrix, Santa Clara, 
CA). Briefly, freshly isolated or cultured cells were snap-frozen in liquid nitrogen. Total 
RNA was extracted using Trizole according to instructions provided by the 
manufacturer. Because of small amounts of RNA in freshly isolated cells, cRNA was 
obtained according to the GeneChip Eukaryotic Small Sample Target Labeling Assay 
Version II (Affymetrix). For all samples, 10 ȝg of cRNA was hybridized to the HG-
U133A array (Affymetrix) representing 22,284 probes and ~14,500 genes. Arrays were 
scanned at 3 ȝm using the Agilent Gene Array Scanner (Affymetrix). Gene expression 
data were analyzed using the Affymetrix Microarray Suite (MAS) 5.0, Affymetrix 
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MicroDB 3.0 and Affymetrix Data Mining Tool (DMT) 3.0 programs. Briefly, a target 
value of 100 was set for scaling signal intensities of all probe sets. For each comparison, 
differentially expressed genes were obtained as follows: genes with a present or 
marginal call in one or both populations were selected. Only genes that showed 
increased or decreased calls were kept for further analysis. Within these genes, only 
those with a log2 ratio >1.6 or < -1.6 in paper I and ratio >1 or < -1 in paper II were 
selected and published using MicroDB 3.0 into DMT 3.0 to obtain gene names and 
descriptions. Raw data for the microarray analyses are available at: 
http://www.ebi.ac.uk/arrayexpress/, under accession no. E-MEXP-167 and E-MEXP-
168 for paper I and accession no. E-MEXP-214 and E-MEXP-215 for paper II. 
7.6  Mesodermal linage differentiation 
Studies on the capability of hMSCs and ADASCs to differentiate along adipogenic, 
osteogenic, and chondrogenic lineages were performed at passage 4. For adipogenic
differentiation, confluent cultures were incubated with DMEM/F12 containing 10% 
FBS or AS, 0.5 μM 1-methyl-3 isobutylxanthine, 1 μM dexamethasone, 10 μg/ml 
insulin  and 100 μM indomethacin for 3 weeks. After differentiation, cells were fixed 
with 4% formalin, washed in 50% isopropanol and subsequently incubated for 10 
minutes with Oil-Red O to visualize lipid droplets. Cells were then washed in
isopropanol and subjected to nuclear staining with hematoxylin. For osteogenic 
differentiation, cells incubated at 3,000 cells per cm2 were incubated in DMEM/F12 
containing 10% FBS or AS, 100 nM dexamethasone, 10 mM -glycerophosphate and 
0.05 mM L-ascorbic acid-2-phosphate for 3 weeks. After differentiation, cells were 
fixed for 1 hour in 4% formalin and rinsed with PBS without Ca2+ and Mg2+.
Mineralization of the ECM was visualized by staining with 40 mM Alizarin Red S, pH 
4.2, for 5 minutes. For chondrogenic differentiation, 1.5-2.0 x 105 cells were pelleted in 
conical tubes in 500 μl chondrogenic induction media containing high-glucose DMEM  
supplemented with 500 ng/ml bone morphogenic protein-6, 10 ng/ml recombinant 
human transforming growth factor- 1, 1 mM sodium pyruvate, 0.1 mM ascorbic acid-2-
phosphate, 100 nM dexamethasone, 1% ITS (25 mg insulin, 25 mg transferrin, and 25 
μg sodium selenite), and 1.25 mg/ml bovine serum albumin. Tissue spheres were 
collected after 4 weeks and fixed overnight in a 0.1-M cacodylate buffered mixture of 
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2% glutaraldehyde and 0.5% paraformaldehyde. The samples were embedded in an 
epoxy resin, and 2-μm-thick sections were cut on a microtome. Sections were then 
stained with a drop of 0.4% acidic toluidine blue solution for 1 minute, rinsed in 
distillated water, mounted and immediately micrographed. 
7.7  Neurogenic differentiation and immunocytochemistry of ADASC 
Cultured cells from polyclonal and clonal cell lines at passage 4 were added to wells in 
48-well plates at a density of 1000 cells per cm2 in DMEM with 4.5 g/l glucose 
containing 10% FBS and antibiotics. To initiate differentiation, the medium was
replaced the following day to also contain B27, 10 ng/ml epidermal growth factor and 
20 ng/ml bFGF. After 5 d, cells were washed and incubated with induction media 
containing DMEM with 5 μg/ml insulin, 200 μM indomethacin and 0.5 mM 1-methyl-3-
isobutylxanthine in the absence of FBS for 5 h. Cells were fixed in methanol at 20°C for 
10 min and washed. Immunocytochemistry was performed using standard methods. In
brief, cells were blocked with 10% FBS and 5% milk and incubated with a polyclonal 
antibody against Neurofilament 200 or a MAb against glial acidic fibrillary protein
overnight at 4°C. After washing, cells were incubated with goat anti-rabbit antibody 
conjugated to Cy2 for 2 h. An inverted phase contrast microscope with camera and 
controller software was used to capture images. 
7.8  Electron microscopy 
CA-ECM were fixed in a phosphate-buffered mixture of paraformaldehyde and 
glutaraldehyde and embedded at low temperature in Lowicryl HM23 (Chemische 
Werke, Waldkraiburg, Germany). Ultrathin sections were subjected to immunogold 
analysis against Col1, Col2 antibodies using protein A coated with 10-nm colloidal gold 
for detection. Electron micrographs were sampled randomly with respect to distribution 
of gold particles, and marker density for each tissue compartment was measured by 
semiautomatic interactive image analysis. 
68
7.9  Chromatin immunoprecipitation 
Chromatin immunoprecipitation (ChIP) was performed in buffers containing 20 mM 
sodium butyrate (Dahl and Collas, 2007) with a few modifications. In short, cells were 
crosslinked with formaldehyde, lysed in lysis buffer/2% SDS, sedimented, and the 
pellet was sonicated in lysis buffer/1% SDS to produce chromatin fragments of ~300 
bp. ChIPs were performed using 100 ȝl sonicated chromatin (corresponding to ~5000 
cells) and antibodies to acetylated H3K9 (H3K9ac), which is known as a marker of 
active genes, and trimethylated H3K9 (H3K9m3) and H3K27m3, which are epigenetic 
markers for silent genes. Immunoprecipitated DNA was used as template for 
quantitative PCR. Primers used were COL1A1, COL2A1 promoter regions and COL2A1 
enhancer region relative to their transcription start sites to investigate mechanisms of 
chondrocyte dedifferentiation. 
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8.  DISCUSSION 
Isolated living and healthy cells from the body in the form of freshly isolated cells, ex
vivo expanded cells or cells combined with biocompatible carrier materials as explants 
have been used in vivo in a variety of tissues to maintain healthy tissue (homeostasis) 
and repair damaged tissue. Much progress has been made recently in tissue engineering, 
particularly with adult stem cells in preclinical research, on the cell source for tissue 
substitute, ex vivo amplification and differentiation, and 3D tissue organization, but 
there are still many engineering and biological challenges ahead. Using human adult 
somatic cells in the clinic requires cells with well characterized profiles, controlled 
culture conditions during expansion with good quality (Benya and Shaffer, 1982; Miura 
et al., 2006; Rodriguez et al., 2005; Talens-Visconti et al., 2007; Zhao et al., 2002). 
In this thesis, I have tried to characterize some essential biological principles for human 
adult stem cells and chondrocytes which may be of use in regenerative medicine. 
Freshly isolated MSC from bone marrow have been too few or insufficiently pure to be 
thoroughly characterized. We took advantage of the availability of large numbers of 
MSC from adipose tissue to perform characterization of freshly isolated human 
ADASC. These results were then compared with similar results obtained from cultured 
ADASC in order to understand the changes induced in these cells by in vitro culture.  
Furthermore, optimal culture conditions for expansion of hMSCs and alternative 
autologous nutrition for FBS has also been explored. To produce therapeutically useful 
hAC numbers without losing collagen type II synthesis and secretion has also been 
studied.
Paper I: 
Recent studies have shown that human SVF of adipose tissue contains a potent supply 
of a subset of hMSC. Although cultured stem cells isolated from SVF have been 
extensively characterized, little was known about the phenotypical and gene expression 
characteristic of freshly isolated cell populations in the SVF of human adipose tissue. 
In paper I, after removing the CD45+ population, we isolated two populations of CD45-
CD34+CD105+ from human SVF of adipose tissue, which were separated based on 
CD31 expression. CD31 (PECAM-1) is commonly used for labeling endothelial cells 
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(EC), but is also expressed by monocytes, platelets, lymphocytes, and granulocytes 
(Wosnitza et al., 2007). Freshly isolated CD31+ and CD31- and cultured CD31- cells 
were extensively examined for cell surface and intracellular molecule expression. We 
demonstrated that all CD31+ cells expressed both CD34 and CD105 with high intensity, 
while most, but not all CD31- cells expressed these markers (Figure 1A, and 1B, paper 
I).
The most remarkable differences between CD31- and CD31+ cells was expression of 
HLA-DR. CD31-  cells were consistently negative whereas all CD31+ cells expressed 
cell surface HLA-DR (Figure 1C, paper I). Expression of integrins and endothelium-
related molecules was also found more frequently and with higher intensity in CD31+
cells than CD31- cells (Table 1, paper I). 
Global gene expression analysis has shown that only a few hundred probes out of 
22,000 were differentially expressed more than three fold between CD31- and CD31+
subsets. Briefly, a number of transcripts involved in cell cycle arrest, stem cell biology, 
development and biology of adipose tissue, bone, cartilage, muscle and neuronal tissue 
were upregulated in CD31- cells. Transcripts associated with endothelium, transcripts 
related to the MHC class II complex, antigen presentation, cytokines and cytokine 
receptors and proteins involved in signal transduction and transcription were 
upregulated in CD31+compaired with CD31-.
In contrast to CD31+cells, the CD31- population in culture displayed proliferative and 
multilineage differentiation capacity in vitro. Culture of CD31- and CD31+ cells 
separately revealed that the CD31+ cells did not plate and remained as suspended 
aggregates that did not proliferate under standard culture conditions used for adherent 
cells. In contrast, about half of the freshly isolated CD31- cells attached to the plastic 
surface displayed fibroblastic-like morphology after 1-2 days. Of the remaining CD31-
cells, some of them attached later, while the rest remained in suspension and finally 
died. Surprisingly, the CD31- population, which contained predominantly CD34+ cells, 
lost its expression of CD34 in culture at passage 4. Results of other studies 
characterizing human SVF cells are in line with our observations showing that CD34+
expression was not found in cells cultured for more than 2 weeks under conventional 
culture conditions (Zuk et al., 2002; Katz et al., 2005; Lee et al., 2004). This 
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observation was also confirmed at the transcriptional level, where CD34 antigen 
expression was downregulated 6 fold in cultured cells at passage 4 compared with 
uncultured CD31- cells (Table 5, paper I). 
We generated several monoclonal colonies from the CD31- populations. Of note, only 
16% (63/384) of seeded single cells adhered to the plastic. Many of these cells failed to 
produce CFU-F after 3 weeks, and only 15 clones (15/384, or 4% of entire CD31- cells) 
could be expanded to more than 106 cells (20 population doublings). However, when 
polyclonal CD31- cells were seeded, approximately half of the cells attached to plastic 
after two days, and most of these spread and formed colonies. The difference in 
attachment and colony forming efficiency between the seeding of single and polyclonal 
cells may be explained by the observation that MSCs, upon attachment to plastic, 
secrete the Wnt inhibitor dickkopf-1 (Dkk-1). The addition of Dkk-1 to MSC cultures 
has been shown to induce entry into the cell cycle (Gregory et al., 2005). In our 
polyclonal cultures, some cells may be early attachers and secrete Dkk-1 upon 
attachment. The presence of Dkk-1 in the culture may induce slow attachers to attach 
and proliferate. These cells could potentially be lost in clonal cultures, where Dkk-1 
from neighboring cells would not be present. It should be noted that the culture 
conditions used here are extremely stringent, with no growth factors added and no 
coating on the plastic surface, so the cloning and colony forming efficiency described 
must be considered as low estimates. The observation that approximately half of the 
CD31- cells in polyclonal cultures attached and formed colonies strongly suggest that 
some colonies are formed from CD34+ cells, as the proportion of CD34- cells within the 
CD31- population never approached 50% (data not shown). 
After in vitro expansion, CD31- cells were studied by flow cytometry and microarray 
analyses and compared with their uncultured counterparts. Surface marker expression 
did not differ greatly between uncultured and cultured CD31- cells. The most apparent 
changes in cultured cells were found within the group of integrins and adhesion 
molecules, where expression of several molecules was upregulated in culture. Other 
obvious changes were upregulation of MSC-related CD105 and loss of CD34 
expression. Cultured CD31- cells were capable of undergoing multilineage 
differentiation.
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The phenotype and gene expression profile of CD31- and CD31+ cells are sufficiently 
similar to suggest ontogenetic linkage. The data from our study and others may also 
suggest interactions between CD31- and CD31+ cells in adipose tissue. Very recently, 
the functional properties of CD31- CD34+ as progenitor cells that may be induced to 
differentiate towards an endothelial phenotype in the presence of conditioned medium 
from cultures of CD31+ CD34+ cells has been reported (Sengenes et al., 2007). This 
study demonstrated that the G-protein-coupled seven-span transmembrane receptor 
CXCR-4 is expressed on CD31- CD34+ progenitor cells, and stromal derived factor-1 
(SDF-1), the sole ligand of CXCR-4, is produced by CD31+ CD34+ cells. CD31+ CD34+
cells induce chemotaxis and promote the differentiation and organization of CD31-
CD34+ progenitor cells into capillary-like structures via a SDF-1/CXCR-4-dependent 
pathway in vitro (Sengenes et al., 2007). 
Our data also demonstrates that CD31- and CD31+ cells are two large and distinct 
populations in SVF of human adipose tissue. Live cell imaging from this tissue has 
revealed that adipogenesis takes place within adipogenic/angiogenic clusters that also 
contain various stromal cells and blood vessels where angiogenesis is an essential part 
of adipogenesis (Nishimura et al., 2007). Recent research findings has also postulated 
that adipocytes and endothelial cells may share a common progenitor (Planat-Benard et 
al., 2004). SVF cells have been shown to be able to induce change from mature fat cells 
into endothelial cells (Planat-Benard et al., 2004). During the reverse differentiation 
pathway, CD31+ mature endothelial cells from the SVF have been shown to be 
converted to adipocytes (Wosnitza et al., 2007). Our data in paper I also demonstrated 
that CD31+ cells overexpressed endothelial-related genes such as VEGFR1 and 
VEGFR2. Administration of anti VEGF antibodies have been shown to inhibit not only 
angiogenesis but also formation of adipogenic/angiogenic cell clusters, indicating that 
coupling of adipogenesis and angiogenesis is essential for differentiation of adipocytes, 
and that VEGF is a key mediator of that process (Nishimura et al., 2007). 
In comparison, freshly isolated, uncultured CD31- cells overexpressed transcript 
associated with different mesodermal organs. We also observed overexpression of 
transcripts related to fat metabolism and several complement components, which is 
likely to be related to the function of those cells as precursors of adipocytes (Kershaw 
and Flier, 2004). Recently, it has also been shown that freshly isolated CD31- cells are 
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100% positive for S100 as an early marker of adipogenesis (Wosnitza et al., 2007). 
Thus, adipose tissue contains a CD31- population with preadipocyte characteristics and 
the capacity to differentiate into adipocytes as well as endothelial precursor and mature 
endothelial cells. In addition, CD31+ cells with an endothelial phenotype can be 
converted into adipocytes under adequate differentiation conditions. Consequently, 
CD31+ and CD31- populations in human adipose tissue are well connected to each other 
and control their own regulation and differentiation. Since several cell types reside in 
adipose tissue, the thorough interactions, functions and ontogenetic linkage of these 
cells need to be investigated in greater detail. 
Paper II: 
While clinical studies using hMSC have already been performed, the challenge of  
generating the best possible culture conditions for clinical scale production of hMSCs  
is still being discussed (Sotiropoulou et al., 2006b); (Dimarakis and Levicar, 2006); 
(Berger et al., 2006; Sotiropoulou et al., 2006a). Although hMSCs themselves are not 
highly immunogenic (Le et al., 2003; Le, 2003), when expanded in FBS they are likely 
to generate xenogeneic immune responses. Recently, it has been shown that uptake of 
FBS protein by MSCs is an active process that leads to an intracellular accumulation of 
bovine antigen even when concentrations as low as 2% of FBS are used in the 
expansion medium (Gregory et al., 2006). A previous study by the same group has also 
shown that a single preparation of 108 hMSCs grown under standard conditions in FBS 
could carry 7-30 mg of FBS proteins (Spees et al., 2004). 
In a clinical trial using MSC for the treatment of osteogenesis imperfecta, a patient was 
identified with antibodies against bovine serum proteins after treatment with hMSCs 
expanded in FBS. This patient did not exhibit successful cellular engraftment (Horwitz 
et al., 2002). Anaphylactic reactions have been reported in several patients who have 
received repeated administrations of dendritic cells or lymphocytes cultured in FBS 
(Mackensen et al., 2000); (Selvaggi et al., 1997; Tuschong et al., 2002). Most recently, 
an interesting study has shown that FBS-primed dendritic cells induce a strong anti-FBS 
immune response in the non-obese diabetic (NOD) mouse (Kadri et al., 2007). Also, 
FBS proteins have been implicated in prion transmission (Kuznetsov et al., 2000). Thus, 
the use of FBS as a cell culture supplement is not recommended (Doucet et al., 2005). 
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Obviously, these data indicate that both clinical and regulatory issues necessitate a 
search for serum supplements other than FBS. Allogeneic human serum might represent 
an acceptable alternative, but expansion of hMSCs in allogeneic serum has not been 
successful. We used a commercially available pool of human sera and observed growth 
arrest in hMSC cultures (paper II). Other investigators were also unable to grow hMSCs 
in commercially available human serum (Spees et al., 2004). Serum free and serum 
substituted media have been investigated, but no protein or peptide free culture medium 
has been published to support the proliferation of hMSCs in the absence of growth 
factors. Most studies have concluded that serum free media cannot promote MSC 
growth without the addition of cytokines (Gronthos and Simmons, 1995; Kuznetsov et 
al., 1997a). This is probably due to the fact that serum contains nutritional components 
essential to MSC proliferation and differentiation. 
Recently, human platelet lysate (hPL) has been identified as a promising supplement to 
culture media (Doucet et al., 2005; Kocaoemer et al., 2007). Human platelets contain 
factors such as platelet-derived growth factors (PDGFs), basic fibroblastic growth factor 
(b-FGF), vascular endothelial growth factor (VEGF), insulin-like growth factors-I (IGF-
I) and TGF-ȕ (Doucet et al., 2005; Eppley et al., 2004). PL is a fluid containing high 
concentration of these growth factors. It is obtained by lysing the platelet bodies, and 
then mixing the lysate in a small volume of blood plasma (Bernardo et al., 2007). 
Several studies have successfully expanded hMSCs in hPL better than in FBS-
containing media, but the differentiation capacity and immunosuppressive function of 
expanded MSCs in hPL-containing media have been contradictory (Gruber et al., 2004; 
Doucet et al., 2005; Bernardo et al., 2007; Kocaoemer et al., 2007; Lange et al., 2007; 
Muller et al., 2006). 
In fact, the main aim of in vitro MSC expansion for therapy is, first and foremost, 
maximal increase in cell numbers while retaining an undifferentiated profile. Growth 
factors present in hPL promote MSC proliferation. However, MSCs express receptors 
for PDGF-A, -B, bFGF, TGF-ȕ and IGF-I growth factors (Doucet et al., 2005), which 
may induce differentiation signals in the proliferating MSCs. Also, since hPL is derived 
from platelets obtained from a pool of allogeneic donors, concerns about immunological 
reactions must again be raised. Human platelet surface glycoprotein molecules are 
suitable targets of alloimmune recognition and can result in activation of T cells and 
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formation of alloantibodies in recipients (Rozman, 2002). Investigators intending to use 
human allogeneic serum or platelet derived media instead of autologous serum, desire to 
obtain an “off-the-shelf” product that will be available in large quantities for the 
expansion of large numbers of MSCs required for repetitive transplantations (Baksh et 
al., 2004; Kocaoemer et al., 2007). 
In paper II of this thesis, I have shown that expansion of hMSCs in AS in the absence of 
FBS and without addition of any cytokines is as effective as supplementing the culture 
medium with FBS. However, in hMSC cultures supplemented with commercially 
pooled alloHS, fewer cells attached and formed colonies, and cultured cells never 
reached 60% subconfluence in the first passage, which is in line with other studies 
(Spees et al., 2004). 
Using staining assays, we showed that hMSCs expanded in AS differentiated more 
slowly towards adipogenic and chondrogenic lineages than did hMSCs expanded in 
FBS. Changes in gene expression confirmed these differences. Genes associated with 
differentiation in osteoblasts, adipocytes, and chondrocytes were overexpressed in 
hMSC cultures supplemented with FBS rather than in AS. Interestingly, differentiation 
of hMSCs cultured in media supplemented with hPL was also inhibited (Bernardo et al., 
2007; Lange et al., 2007). A time-delay of fat droplets and a decreased number of cells 
converting to adipocytes in line with downregulation of genes participating in fatty acid 
metabolism, e.g. apolioprotein E (ApoE) and sterol regulatory element binding 
transcription factor 2 (SREBF2) has been reported in hMSCs expanded in human 
platelet-derived medium (Lange et al., 2007). Together, this pattern of genes 
overexpressed in hMSCs grown in FBS suggest that FBS may contain differentiation 
factors that are not found in human supplements such as AS and PL. Thus, compared 
with cells expanded in FBS, hMSCs expanded in AS seemed less changed and remained 
transcriptionally more stable after four passages. This tendency was confirmed by long 
term cell expansion where the lists of genes differentially expressed in FBS and AS 
supplemented hMSCs between passage 4 and 10 were analyzed. Many genes were up- 
and downregulated in hMSCs expanded in FBS between passages 4 and 10. In contrast, 
gene expression in hMSCs supplemented with AS was extremely stable over this same 
period of time. Surprisingly, no genes were upregulated in any of the donors examined, 
and only a few genes were downregulated. Thus, hMSCs could be expanded in culture 
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medium supplemented with AS for therapeutic purposes without risk of transcriptome 
instability. 
The immunosuppressive effect exerted by hMSCs has been linked to production of 
prostaglandins (Aggarwal and Pittenger, 2005). Several prostaglandin synthesis genes 
were highly upregulated in FBS-supplemented hMSCs, suggesting that hMSCs 
expanded in AS may have a lesser immunosuppressive effect than cells cultured in FBS. 
In harmony with our results, hMSCs cultured in human platelet lysate displayed an 
apparently weaker immunosuppressive effect than cells expanded in FBS (Bernardo et 
al., 2007). Whether these weaknesses in differentiation potential and 
immunosuppressive effect of hMSCs cultured in human supplements such as AS and  
PL interfere with their in vivo functions, or just represent the consequence of in vitro 
culture, remains to be investigated. 
Genes associated with the cell cycle were overexpressed in hMSCs cultured in FBS and 
were all associated with prolongation of the cell cycle, which is consistent with different 
rates in cell proliferation. At passage 10, hMSCs in FBS were closer to replicative 
senescence than hMSCs in AS. In addition, cumulative cell counts were always much 
higher for hMSCs cultured in AS as compared to FBS. Thus, this study has shown that 
hMSCs could be expanded rapidly to very high cell counts in the presence of AS 
without growth factors. 
 Undoubtedly, in the clinical setting where patient blood collection is not possible, 
platelet-derived culture medium for cell expansion may be a proper alternative to FBS. 
Paper III 
Trauma, inherited abnormalities and osteorthritis may lead to damage of articular 
cartilage. With the protective cartilagenous layer damaged or gone, joint movement may 
lead to the grinding of one bony surface on the exposed, osseous surface of the other. 
This may be very painful, and lead to a decrease in quality of life. Poor healing capacity 
of cartilage has resulted in the emergence of numerous strategies to repair or replace 
damaged cartilage surfaces. 
Chondrocytes residing within cartilage are the most applied cell source to regenerate 
cartilage tissue, but they are limited in number, and monolayer expansion leads to 
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dedifferentiation or loss of phenotype. The dedifferentiation of hAC cultured 
monolayers is fast, occurring as early as first passages (az-Romero et al., 2007; Darling 
and Athanasiou, 2005b). During this process, chondrocytes lose their rounded shape and 
produce less of hyaline cartilage-specific matrix proteins, such as collagen type II, and 
behave more like a fibroblastic cell type, producing increased amounts of collagen type 
I (Schnabel et al., 2002). ACI studies, in which the patient’s own cells have been 
isolated from cartilage biopsy, expanded in monolayers and then sealed in a defect with 
a periosteal patch, have demonstrated the occurrence of fibrous tissue formation that is 
indicative of dedifferentiated chondrocytes (Grigolo et al., 2005; Knutsen et al., 2004). 
To obtain regenerated cartilage with adequate mechanical properties, these cells need to 
synthesize appropriate amounts of hyaline cartilage-specific proteins. It is desirable 
either to prevent dedifferentiation or to induce redifferentiation capacity during 
chondrocyte expansion. Therefore, for cartilage tissue engineering using autologous 
chondrocyte transplantation to be more successful, the cells expanded in vitro need to 
expresses a hyaline chondrocyte phenotype. 
In paper III, we tried to improve the ACI cell proliferation protocol in order to expand 
AC in vitro to clinically useful cell numbers without losing its hyaline cartilage 
characteristics. ACs were cultured attached to their own pericellular matrix 
(PCM)/ECM in loose structures termed chondrocytes in autologous ECM (CA-ECM). 
Cultures with chondrocytes adherent to plastic as monolayer or supported by their own 
ECMs, CA-ECM, were established.
In monolayers, COL2A1 expression was very low or absent. For CA-ECM cultures, 
biopsies were briefly digested with collagenase, and ACs were allowed to proliferate in 
their own PCM/ECM. Here, chondrocytes were found to be small and rounded. ACs in 
CA-ECM proliferated rapidly, expressed COL2A1 and secreted translated protein into 
the ECM in an organized manner at P0 and P1. EM images of immunogold staining 
demonstrated long and ordered fibrils containing dense COL2 epitopes within newly 
formed ECM. 
At the end of P1, COL2A1 mRNA expression was quite well conserved in CA-ECM 
after 2 weeks of culture. At this stage, chondrocytes in CA-ECM migrated increasingly 
onto the plastic surface to form a monolayer culture and started to develop a 
78
fibroblastic-like appearance. COL2A1 mRNA expression was gradually reduced with 
each passage, but only reached very low levels from P2 onward, when CA-ECM were 
completely dissolved and the cells were expanded as monolayer cultures. However, 
after 2 weeks in culture, the mRNA level of COL2A1 in CA-ECM was at least 100-fold 
higher than in those initially expanded as filtrated single cells in monolayer. At this 
stage, an average cell number of 40 x 106 or more were obtained.  
The SOX9 mRNA levels followed the pattern of COL2A1 mRNA expression when 
chondrocytes were cultured in CA-ECM, and its expression declined when CA-ECM 
dissolved and cells were expanded as a monolayer. SOX9, which is expressed during 
embryonic development, is closely related to cartilage matrix synthesis (Bell et al., 
1997) and exerts its properties by activating the gene for collagen type II and other 
cartilage-specific genes (Lefebvre et al., 1997; Ng et al., 1997; Xie et al., 1999). 
Recently, direct application of a recombinant adeno-associated virus (rAAV) SOX9
vector in vitro and in situ has indicated that sustained expression of a SOX9 gene 
cassette significantly increased the proteoglycan and type II collagen content in 3D 
cultures of human normal and OA chondrocytes (Cucchiarini et al., 2007), consistent 
with the effects of SOX9 leading to expression of cartilage matrix components (Bell et 
al., 1997; Lefebvre et al., 1997; Ng et al., 1997; Tew et al., 2005). This is consistent 
with the possibility that, also in CA-ECM cultures, COL2 synthesis is predominantly 
regulated at the level of the transcription factor SOX9. Moreover, our results indicate 
that the synthesis of proteoglycan aggrecan and COL2, two main key elements of 
cartilage ECM, are persistent in CA-ECM without any exogenous induction. 
The concentration of COL1A1 mRNA was high at the end of P0 after about 9 days, and 
could be found to remain at this level through several passages as monolayer cultures 
(data not shown). This trend was associated with high levels of intracellular COL1 
protein as shown by flow cytometry analysis. However, COL1 was not detected in 
newly generated ECM in CA-ECM nor in the original ECM, as shown by EM 
immunogold staining. A possible explanation for the absence of COL1 in the new ECM 
of CA-ECM could be that release of COL1 into the ECM was blocked. 
To identify epigenetic mechanisms involved in the dedifferentiation process of AC, we 
performed ChIP assays (Dahl and Collas, 2007) to map histone H3 modification 
79
associated with the COL2A1, COL1A1 promoter and COL2A1 enhancer regions at P1 
and P3 in two different incubator gas compositions. We found that COL1A1 promoter 
was associated with a high level of H3K9ac, which is a marker of active genes, while 
trimethylated H3K9 and H3K27, which are epigenetic markers of silent genes, were 
absent. The H3 modifications on COL2A1 showed low levels of H3K9ac. At the same 
time, H3K9m3, which is considered to be associated with constitutive transcriptional 
repression, was also low for both loci at both time points. These H3 modifications on 
COL2A1 suggest that the gene is accessible to transcription factors, and that this may be 
the predominant mechanism involved in the regulation of COL2A1 expression. 
However, a high level of H3K27m3 in the promoter region is consistent with an 
epigenetic mechanism of transient transcriptional repression.
In conclusion, we have shown that ACs expanded in CA-ECM in vitro proliferate 
rapidly, while the dedifferentiation process is slowed sufficiently to yield clinically 
useful numbers of chondrocytes producing COL2 at the end of two weeks in culture. 
These results may improve clinical protocols for ACI. 
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9.  CONCLUSION 
The data presented in this thesis demonstrate that; 
¤ Human adipose tissue contains a CD45- CD34+CD105+ CD31- population with stem cell 
properties.
¤ Cultured CD45-CD34+CD105+CD31- cells differ from their uncultured counterparts. 
¤ hMSCs are expanded rapidly to high cell counts in the presence of AS without growth 
factors.
¤ Compared with cells expanded in FBS, hMSCs in AS are less differentiated and 
remained transcriptionally more stable over time in culture. 
¤ hACs expanded in vitro in CA-ECM are rapidly proliferated to clinically useful 
numbers while maintaining COL2 expression. 
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